Assay for MYBPC3
Patent Information
- Application Number
- CN202411086104.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-07-31
- Filing Date
- 2023-11-01
- Publication Date
- 2024-11-12
AI Technical Summary
The prior art is difficult to detect myomyosin-binding protein C (MYBPC3) with high sensitivity in the diagnosis of acute myocardial infarction, especially in distinguishing between type 1 and type 2 myocardial infarction and predicting the risk of patients with acute coronary syndrome.
Monoclonal antibodies bound to MYBPC3, including 7B5 and 4.1.1 antibodies and their fragments, were developed for sandwich assays, by forming complexes with MYBPC3 in the sample to assess heart conditions such as myocardial infarction or heart failure.
A high-sensitivity MYBPC3 detection is achieved, which improves the diagnostic accuracy of myocardial infarction and heart failure, and can distinguish type 1 and type 2 myocardial infarction, predicting the risk of patients with acute coronary syndrome.
Smart Images

Figure BDA0004985222470000341 
Figure BDA0004985222470000342 
Figure BDA0004985222470000351
Abstract
Description
[0001] This application is a divisional application of an invention patent application with an application date of November 1, 2023, an application number of 202311442484.0, and an invention name of “Determination of MYBPC3”. Technical Field
[0002] The present invention relates to monoclonal antibodies or fragments thereof that bind to MYBPC3 (Myosin Binding Protein C, Cardiac). Further, the present invention relates to a kit comprising the monoclonal antibody of the present invention. In some embodiments, the kit is provided as a sandwich assay. The present invention further relates to the in vitro use of the monoclonal antibody or fragment thereof, or the kit of the present invention for the detection of MYBPC3 in a sample. In addition, the present invention relates to diagnostic methods, such as the assessment of cardiac conditions, for example myocardial infarction. Background Art
[0003] Modern medicine aims to provide personalized treatment plans. These are treatment plans that take into account the individual needs or risks of the patient. Personalized treatment plans should even be considered for emergency measures where a decision on possible treatment options needs to be made within a short period of time. In such settings, blood tests to measure circulating biomarkers can help diagnose the disease state (such as troponin tests to help diagnose myocardial cell damage).
[0004] According to the unified definition of acute myocardial infarction (AMI) (Thygesen K et al., Circulation 2018; 138: e618-e651.doi: 10.1161 / CIR.0000000000000617.), five different types of AMI are defined based on the different mechanistic pathways behind AMI, such as type 1 and type 2 myocardial infarction. The diagnostic workup of patients suspected of having AMI (acute myocardial infarction) requires admission to the emergency room, recording of a 12-lead electrocardiogram (ECG), blood tests to diagnose or exclude myocardial injury, assessment of clinical symptoms and medical history, physical examination, and other diagnostic tests for diagnosis of AMI or differential diagnosis. For patients who are not included or excluded with high-sensitivity troponin, the diagnosis and management of ACS (acute coronary syndrome) remains challenging. Using the 1-hour algorithm of high-sensitivity troponin, between 20% and 25% of patients suspected of having an AMI (acute myocardial infarction) remain in the observation zone, including patients who were not classified as included / excluded after two consecutive measurements at T0 and T1. Using the rapid protocol (0-hour algorithm according to the ESC (European Society of Cardiology) guidelines), even up to 70% of patients suspected of having an AMI remain in the waiting zone (patients who were not classified as included / excluded after a single measurement at T0).
[0005] Cardiac myosin binding protein C (MYBPC3, alternative abbreviations: cMyBPC, cMyc or MYBPC3, cMyBP-C) is the cardiac isoform of MyBP and is a structural myoprotein of cardiomyocytes. MYBPC3 has high cardiac specificity and is released into the bloodstream after myocardial necrosis. MYBPC3 is a highly specific cardiac protein associated with myocardial contraction. Its specific role and high abundance in the myocardium make it an excellent biomarker candidate for myocardial damage in the circulation. It is reported that the concentration of myocardial necrosis biomarkers in blood samples of patients with acute myocardial infarction is increased. In addition, differences in the concentration of MYBPC3 were observed in patients with type 1 MI and type 2 MI (see, for example, Nestelberger et al., 2021JAMA Cardiol.doi:10.1001 / jamacardio.2021.0669).
[0006] Kozhuharov et al. disclosed that MYBPC3 can be used for the diagnosis and risk stratification of acute heart failure (Eur J Heart Fail. 2021 May;23(5):716-725. doi:10.1002 / ejhf.2094. Epub 2021 Feb 5 PMID:33421273).
[0007] Kaier et al. disclosed an algorithm for early diagnosis of myocardial infarction using cardiac myosin-binding protein C (European Heart Journal. Acute Cardiovascular Care, Vol. 11, No. 4, April 2022, pp. 325-335).
[0008] WO 2015 / 110114 and WO 2015 / 110115 disclose monoclonal antibodies that bind to MYBPC3.
[0009] Marjot et al describe the development and application of a highly sensitive immunoassay for cardiac myosin-binding protein C. Transl Res 2016;170:17–25.e5.
[0010] However, there is still a need for MYBPC3 assays that are able to detect biomarkers with high sensitivity. It is therefore an object of the present invention to provide means and methods that allow for reliable detection of MYBPC3.
[0011] The inventors have identified two antibodies, designated mAB "7B5" and mAB "4.1.1", that are particularly useful for the detection of MYBPC3. Antibodies 7B5 and mAB "4.1.1" recognize a non-linear conformational epitope presented by the natively folded MYBPC3 protein (see Tables 7 and 8 of the Examples section). In particular, the antibodies can be used as antibody pairs in sandwich assays. The sandwich assays of the invention allow for the assessment of cardiac conditions, such as myocardial infarction or heart failure. Summary of the invention
[0012] The present invention relates to monoclonal antibodies or fragments thereof that bind to MYBPC3 (Myosin Binding Protein C, Cardiac Type).
[0013] In a first aspect, the present invention relates to a first monoclonal antibody or fragment thereof that binds to MYBPC3 (myosin binding protein C, cardiac type). The first antibody or fragment thereof described herein is preferably an antibody or antigen-binding fragment thereof designated as 7B5. The amino acid sequences of the light chain and heavy chain variable domains and CDR sequences of the antibody designated as 7B5 are Fig.11 However, the first monoclonal antibody or its fragment is not limited to this antibody. The present invention further encompasses variants of this antibody or its fragment, provided that the variant binds to MYBPC3.
[0014] In a preferred embodiment, the first monoclonal antibody or fragment thereof comprises a first light chain variable domain and / or a first heavy chain variable domain,
[0015] (a) the first light chain variable domain comprises
[0016] (a1) a first light chain CDR1 that differs from the first light chain CDR1 having the amino acid sequence shown in SEQ ID NO:1 (QASQSIGNALA) by no more than a total of three amino acid additions, substitutions and / or deletions,
[0017] (a2) a first light chain CDR2 that differs from the first light chain CDR2 having the amino acid sequence shown in SEQ ID NO:2 (STSYLPS) by no more than a total of three amino acid additions, substitutions and / or deletions, and / or
[0018] (a3) a first light chain CDR3 that differs from the first light chain CDR3 having the amino acid sequence shown in SEQ ID NO: 3 (QSYYVSTSSSDRSS) by no more than a total of three amino acid additions, substitutions and / or deletions,
[0019] (b) the first heavy chain variable domain comprises
[0020] (b1) a first heavy chain CDR1 that differs from the first heavy chain CDR1 having the amino acid sequence shown in SEQ ID NO:4 (SGYDMC) by no more than a total of three amino acid additions, substitutions and / or deletions,
[0021] (b2) a first heavy chain CDR2 that differs from the first heavy chain CDR2 having the amino acid sequence shown in SEQ ID NO:5 (CIGSSSASTWYANWVNG) by no more than a total of three amino acid additions, substitutions and / or deletions, and / or
[0022] (b3) a first heavy chain CDR3 that differs from the first heavy chain CDR3 having the amino acid sequence shown in SEQ ID NO:6 (ESSTEYYYNL) by no more than a total of three amino acid additions, substitutions and / or deletions.
[0023] In a preferred embodiment, the first monoclonal antibody or fragment thereof comprises
[0024] (a) a first light chain variable domain comprising
[0025] (a1) the first light chain CDR1, which differs from the first light chain CDR1 having the amino acid sequence shown in SEQ ID NO:4 (QASQSIGNALA) by no more than one amino acid addition, substitution or deletion,
[0026] (a2) the first light chain CDR2, which differs from the first light chain CDR2 having the amino acid sequence shown in SEQ ID NO:5 (STSYLPS) by no more than one amino acid addition, substitution or deletion, and / or
[0027] (a3) the first light chain CDR3, which differs from the first light chain CDR3 having the amino acid sequence shown in SEQ ID NO:6 (QSYYVSTSSSDRSS) by no more than one amino acid addition, substitution or deletion,
[0028] (b) a first heavy chain variable domain comprising
[0029] (b1) a first heavy chain CDR1 that differs from the first heavy chain CDR1 having the amino acid sequence shown in SEQ ID NO:7 (SGYDMC) by no more than one amino acid addition, substitution or deletion,
[0030] (b2) a first heavy chain CDR2 that differs from the first heavy chain CDR2 having the amino acid sequence shown in SEQ ID NO:8 (CIGSSSASTWYANWVNG) by no more than one amino acid addition, substitution or deletion, and / or
[0031] (b3) a first heavy chain CDR3 that differs from the first heavy chain CDR3 having the amino acid sequence shown in SEQ ID NO:9 (ESSTEYYYNL) by no more than one amino acid addition, substitution or deletion, in a particularly preferred embodiment, the first monoclonal antibody or fragment thereof comprises
[0032] (a) a first light chain variable domain comprising
[0033] (a1) the first light chain CDR1 has the sequence shown in SEQ ID NO: 1 (QASQSIGNALA),
[0034] (a2) the first light chain CDR2 has the sequence shown in SEQ ID NO: 2 (STSYLPS), and
[0035] (a3) the first light chain CDR3 has the sequence shown in SEQ ID NO: 3 (QSYYVSTSSSDRSS),
[0036] as well as
[0037] (b) a first heavy chain variable domain comprising
[0038] (b1) a first heavy chain CDR1 having the sequence shown in SEQ ID NO:4 (SGYDMC),
[0039] (b2) a first heavy chain CDR2 having SEQ ID NO: 5
[0040] (CIGSSSASTWYANWVNG), and
[0041] (b3) a first heavy chain CDR3 having SEQ ID NO: 6 (ESSTEYYYNL)
[0042] sequence shown.
[0043] Typically, the first monoclonal antibody or fragment thereof comprises a first light chain variable domain and / or a first heavy chain variable domain, wherein
[0044] The first light chain variable domain is the same as SEQ ID NO:7:
[0045] The light chain variable domain of the sequence shown in DIVMTQTPASVEAAVGGTVTIKC QASQSIGNALAWYQQKPGQPPKLLIY STSYLPSGVPSRFKGGGSGAEYTLTISDLECADAATYYC QSYYVSTSSSDRSSFGGGTEVVVK is at least 85%, such as at least 90% or at least 95% identical to that of the light chain variable domain shown in
[0046] The first heavy chain variable domain is at least 85% identical, such as at least 90% or at least 95% identical to the heavy chain variable domain having the sequence shown in SEQ ID NO:8: QEQLEESGGGLVKPGGTLTLTCKVSGFDFSSGYDMCWVRQAPGKGLESIA CIGSSSASTWYANWVNGRFTVSRSTSLNTVDLKMTSLTVADTATYFCARESSTEYYYNLWGPGTLVTVSS.
[0047] In a preferred embodiment of the first monoclonal antibody or fragment thereof, the first light chain variable domain comprises the sequence shown in SEQ ID NO:7 and the first heavy chain variable domain comprises the sequence shown in SEQ ID NO:8.
[0048] In a second aspect, the present invention relates to a second monoclonal antibody or fragment thereof that binds to MYBPC3 (Myosin Binding Protein C, Cardiac Type).
[0049] The second antibody or fragment thereof described herein is preferably the antibody or antigen-binding fragment thereof named 4.1.1. However, the second monoclonal antibody or fragment thereof is not limited to this antibody. The present invention further encompasses variants of antibody 4.1.1 or fragments thereof, provided that the variant binds to MYBPC3.
[0050] The amino acid sequences of the light chain and heavy chain variable domains and CDR sequences of the antibody designated as 4.1.1 are Fig.11 Shown in.
[0051] In one embodiment, the second monoclonal antibody or fragment thereof comprises a second light chain variable domain and / or a second heavy chain variable domain, wherein
[0052] (a) the second light chain variable domain comprises
[0053] (a1) a second light chain CDR1 that differs from the second light chain CDR1 having the amino acid sequence shown in SEQ ID NO:9 (RASQNIGTNMH) by no more than a total of three amino acid additions, substitutions and / or deletions,
[0054] (a2) a second light chain CDR2 that differs from the second light chain CDR2 having the amino acid sequence set forth in SEQ ID NO: 10 (FASESFS) by no more than a total of three amino acid additions, substitutions and / or deletions, and / or
[0055] (a3) a second light chain CDR3 that differs from the second light chain CDR3 having the amino acid sequence shown in SEQ ID NO: 11 (QQSYNWPFT) by no more than a total of three amino acid additions, substitutions and / or deletions,
[0056] (b) the second heavy chain variable domain comprises
[0057] (b1) a second heavy chain CDR1 that differs from the second heavy chain CDR1 having the amino acid sequence shown in SEQ ID NO: 12 (GYGVN) by no more than a total of three amino acid additions, substitutions and / or deletions,
[0058] (b2) a second heavy chain CDR2 that differs from the second heavy chain CDR2 having the amino acid sequence shown in SEQ ID NO: 13 (MIWGDGSTDYNSVYKS) by no more than a total of three amino acid additions, substitutions and / or deletions, and /
[0059] or
[0060] (b3) a second heavy chain CDR3 that differs from the second heavy chain CDR3 having the amino acid sequence shown in SEQ ID NO: 14 (RDTGGASMDY) by no more than a total of three amino acid additions, substitutions and / or deletions.
[0061] In a preferred embodiment, the second monoclonal antibody or fragment thereof comprises
[0062] (a) a second light chain variable domain comprising
[0063] (a1) a second light chain CDR1 that differs from a second light chain CDR1 having an amino acid sequence as shown in SEQ ID NO:9 (RASQNIGTNMH) by no more than one amino acid addition, substitution or deletion,
[0064] (a2) a second light chain CDR2 that differs from the second light chain CDR2 having the amino acid sequence shown in SEQ ID NO: 10 (FASESFS) by no more than one amino acid addition, substitution or deletion, and / or
[0065] (a3) a second light chain CDR3 that differs from the second light chain CDR3 having the amino acid sequence shown in SEQ ID NO: 11 (QQSYNWPFT) by no more than one amino acid addition, substitution or deletion,
[0066] (b) a second heavy chain variable domain comprising
[0067] (b1) a second heavy chain CDR1 that differs from the second heavy chain CDR1 having the amino acid sequence shown in SEQ ID NO: 12 (GYGVN) by no more than one amino acid addition, substitution or deletion,
[0068] (b2) a second heavy chain CDR2 that differs from the second heavy chain CDR2 having the amino acid sequence shown in SEQ ID NO: 13 (MIWGDGSTDYNSVYKS) by no more than one amino acid addition, substitution or deletion, and / or
[0069] (b3) a second heavy chain CDR3 that differs from the second heavy chain CDR3 having the amino acid sequence shown in SEQ ID NO: 14 (RDTGGASMDY) by no more than one amino acid addition, substitution or deletion.
[0070] In a particularly preferred embodiment, the second monoclonal antibody or fragment thereof comprises
[0071] (a) a second light chain variable domain comprising
[0072] (a1) a second light chain CDR1 having the sequence shown in SEQ ID NO:9 (RASQNIGTNMH),
[0073] (a2) a second light chain CDR2 having the sequence shown in SEQ ID NO: 10 (FASESFS), and
[0074] (a3) a second light chain CDR3 having the sequence shown in SEQ ID NO: 11 (QQSYNWPFT),
[0075] as well as
[0076] (b) a second heavy chain variable domain comprising
[0077] (b1) a second heavy chain CDR1 having the sequence shown in SEQ ID NO: 12 (GYGVN),
[0078] (b2) a second heavy chain CDR2 having the sequence shown in SEQ ID NO: 13 (MIWGDGSTDYNSVYKS), and
[0079] (b3) The second heavy chain CDR3 has the sequence shown in SEQ ID NO: 14 (RDTGGASMDY).
[0080] Typically, the second monoclonal antibody or fragment thereof comprises a second light chain variable domain and / or a second heavy chain variable domain, wherein the second light chain variable domain is at least 85%, such as at least 90% or at least 95% identical to the light chain variable domain having the sequence shown in SEQ ID NO: 15 (DILMTQSPAILSVSPGERVSFSCRASQNIGTNMH WYQQRTNGSPRLLIR FASESFS GIPSRFSGTGSGTDFTLRINSVESEDIADYYCQQSYNWPFT FGAGTKLELK), and the second heavy chain variable domain is identical to the light chain variable domain having the sequence shown in SEQ ID NO: 16 (QVQLKESGPGLVAPSQSLSITCTVSGFSLT GYGVN WVRQPPGKGLEWLG MIWGDGSTDYNSVYKSRLS FASESFS GIPSRFSGTGSGTDFTLRINSVESEDIADYYCQQSYNWPFT FGAGTKLELK). The heavy chain variable domains of the sequences shown in (WGQGTSVTVSS) are at least 85%, such as at least 90% or at least 95% identical.
[0081] In a preferred embodiment of the second monoclonal antibody or fragment thereof, the second light chain variable domain comprises the sequence shown in SEQ ID NO:15 and the second heavy chain variable domain comprises the sequence shown in SEQ ID NO:16.
[0082] The term "fragment" as used herein generally refers to an "antigen binding fragment". In a preferred embodiment, the fragment of the antibody described herein is a Fab fragment, a Fab' fragment, a Facb fragment, a F(ab')2 fragment, a scFv fragment or a Fv fragment, in particular, the fragment is a F(ab')2 fragment. In one embodiment, the fragment is a F(ab')2 fragment.
[0083] In a preferred embodiment of the monoclonal antibody or its fragment of the present invention, the antibody is labeled. In one embodiment, the monoclonal antibody (or its fragment) is biotinylated. In another embodiment, the monoclonal antibody (or its fragment) is ruthenated. Therefore, the antibody (or its antigen-binding fragment) should contain a ruthenium tag. In one embodiment, the ruthenium tag is a bipyridine ruthenium (II) complex. Alternatively, the antibody (or its antigen-binding fragment) should contain an iridium tag. In one embodiment, the iridium tag is a complex as disclosed in WO 2012 / 107419.
[0084] In a further aspect, the invention relates to a kit comprising a first antibody or fragment thereof and a second antibody or fragment thereof of the invention.
[0085] In one embodiment of the kit of the present invention, the first antibody or a fragment thereof and the second antibody or a fragment thereof are provided as a sandwich assay. Therefore, the kit of the present invention is preferably a sandwich assay. Preferably, the first monoclonal antibody (or a fragment thereof) is biotinylated and the second monoclonal antibody (or a fragment thereof) is ruthenated.
[0086] In a preferred embodiment, the kit comprises a biotinylated F(ab')2 fragment of the first monoclonal antibody described herein and a second monoclonal antibody of the present invention, wherein the second monoclonal antibody comprises an electrochemiluminescent label. The two antibodies form a sandwich immunoassay complex with the MYBPC3 polypeptide in the sample.
[0087] In one embodiment, the kit further comprises a MYBPC3 polypeptide or a fragment thereof (eg, as a control and / or calibrator).
[0088] The amino acid sequence of the full-length MYBPC3 polypeptide is shown in SEQ ID NO: 23. However, the kit is not limited to the full-length polypeptide. Instead, the kit may contain fragments of the full-length polypeptide, provided that they contain the epitope binding region of the antibody of the present invention (see Tables 7 and 8, and Fig.13 and 14 In one embodiment, the fragment comprises the amino acid sequence shown in SEQ ID NO: 17 or 18. Compared with the sequence shown in SEQ ID NO: 18, SEQ ID NO: 17 further comprises a His tag.
[0089] In a further aspect, the present invention relates to an in vitro use of the monoclonal antibody or fragment thereof of the present invention, or the kit of the present invention for the detection of MYBPC3 in a sample. In some embodiments, the detection is a quantitative detection.
[0090] In a preferred embodiment of the use of the method of the invention, the sample is a body fluid (such as a blood, serum or plasma sample).
[0091] The present invention further relates to a method for detecting MYBPC3 in a sample, the method comprising
[0092] (a) contacting a sample comprising MYBPC3 with a first and / or second monoclonal antibody or fragment thereof of the present invention, thereby forming a complex comprising MYBPC3 and said one monoclonal antibody or fragment thereof (or said plurality of monoclonal antibodies or fragments thereof), and
[0093] (b) detecting the complex formed in step (a), thereby detecting MYBPC3 in the sample.
[0094] The present invention further relates to a complex comprising the first and / or second monoclonal antibody or fragment thereof of the present invention and MYBPC3. Preferably, the complex comprises the following:
[0095] i) MYBPC3 peptide
[0096] ii) a first monoclonal antibody or fragment thereof (eg, in biotinylated form), and
[0097] iii) a second monoclonal antibody or fragment thereof (eg, in ruthenated form).
[0098] The present invention further relates to the in vitro use of the monoclonal antibody or fragment thereof of the present invention, or the kit of the present invention for assessing cardiac symptoms.
[0099] In a preferred embodiment, the cardiac condition is heart failure.
[0100] In another preferred embodiment, the cardiac condition is myocardial damage, in particular myocardial infarction.
[0101] In a preferred embodiment of the in vitro use of the invention, myocardial infarction is excluded.
[0102] In another preferred embodiment of the in vitro use according to the invention, type 1 and type 2 myocardial infarction are differentiated.
[0103] In another preferred embodiment of the in vitro use of the present invention, the risk of myocardial infarction and / or cardiac death at 30 days, such as the risk at 30 days, is predicted in a patient suspected of having acute coronary syndrome (ACS). BRIEF DESCRIPTION OF THE DRAWINGS
[0104] Figure 1 : Characterization of purified MYBPC3 by SDS Page and SEC-RALS HPLC
[0105] Figure 2 ELISA of supernatants from B cell or mouse hybridoma cultures
[0106] (a) 96 / 384-well MTP, coated with streptavidin
[0107] (b) Recombinant MYBPC3, monomer, biotinylated via Avi tag
[0108] (c) mAb samples (supernatant of B cell or hybridoma culture)
[0109] (d) Anti-rabbit (anti-mouse)-IgG POD-conjugate
[0110] Figure 3: Kinetic curves of antibody binding to MYBPC3 at 37°C from mouse supernatant. (A) Antibody M-4.000.1 was selected because of its rapid and stable MYBPC3 complex formation with a suitable half-life t / 2diss of >23 minutes (left panel). The dissociation fit (light grey) was superimposed on the measured kinetic curve (right panel). (B) Exemplary kinetic curves of deselected antibodies with slow MYBPC3 complex formation, fast dissociation, or complex binding behavior - not following Langmuir's law or artifact binding.
[0111] Figure 4 : Kinetic characterization of antibody binding to MYBPC3 at 37°C. Interaction of Ab with increasing MYBPC3 concentrations, c = 0.4 nM to 90 nM for antibodies 7B5 (A) and M-4.1.1 (B). 2 independent concentration series (black) are shown, each of which has a concentration of 30 nM in duplicate, superimposed (gray) by the Langmuir 1: 1 fitting model (Rmax global, RI = 0). The first concentration series shows the dissociation phase monitored for 30 minutes (left superimposed graph); both series are "zoomed in" to show the 10 minute dissociation phase (middle and right graphs).
[0112] Figure 5 Overlay of immune MYBPC3 complexes with antibody pairs 4.1.1 and 7B5. Gray upward and downward arrows mark the start and end of injection of (1) MYBPC3 and (2) secondary antibody (here 7B5), respectively.
[0113] Figure 6 : Correlation between Roche and Erenna MYBPC3 measurements. The correlation between the two assays was high (Pearson correlation = 0.894 after log transformation).
[0114] Figure 7 : Results Clinical performance (diagnosis of heart failure). The AUC ("area under the curve") of the Roche MYBPC3 assay was higher compared to the Erenna assay (see graph).
[0115] Figure 8 : Correlation of results: For a total of 1056 patients, Roche and Erenna MYBPC3 measurements were matched. The correlation between the two assays was high (Pearson correlation = 0.9726981).
[0116] Fig. 9: Diagnosis of MI: The AUC of the MYBPC3 assay of the present invention was higher compared to the Erenna assay. AUC was compared using a one-sided DeLong test and the results showed significance (p value = 0.02269). Similar performance was observed in the inclusion zone (lower left) and slightly better performance was observed in the exclusion zone (upper right).
[0117] Fig.10 : Differentiation of Type 1 from Type 2 MI: There were a total of 52 Type 2 and 153 Type 1. The AUC of the Roche assay was higher. The DeLong test did not show significance (p value = 0.1387).
[0118] Fig.11 Amino acid sequences of the variable domains (heavy and light chains) of monoclonal antibodies 7B5 and 4.1.1. The CDR sequences are shown in bold.
[0119] Fig.12 Risk prediction of major adverse cardiovascular events (MACE) within 30 days. AUC values for the assay of the present invention and the Erenna assay are shown.
[0120] Fig.13 The epitope region of antibody M.4.1.1. The binding region of the antibody is in bold and Underline Highlight.
[0121] Fig.14 Epitope region of antibody 7B5. The binding region of the antibody is in bold and Underline Highlight. DETAILED DESCRIPTION
[0122] As mentioned above, the present invention relates to a monoclonal antibody or a fragment thereof that binds to MYBPC3 (Myosin Binding Protein C, Cardiac Type), in particular human MYBPC3.
[0123] MYBPC3 (or MYBPC3) is produced in the myocardium. It is a 140.5 kDa protein composed of 1273 amino acids. MYBPC3 is a myosin-related protein that binds along the main chain of the myosin thick filament at intervals of 43 nm and extends 200 nm on both sides of the M line in the cross-bridge bearing region (C region) of the striated muscle A band. MYBPC3 is encoded by the MYBPC3 gene. More information about human MYBPC3 can be found in the UniProtKB database, with accession number Q14896 (MYPC3_HUMAN). The full-length amino acid sequence is shown in SEQ ID NO: 23 and Fig.13 and 14 middle.
[0124] It should be understood that as used in the specification and claims, "a" or "an" can mean one or more, depending on the context in which it is used. Thus, for example, reference to "an" item can mean that at least one item can be utilized.
[0125] As used hereinafter, the terms "having", "including" or "comprising" or any of their grammatical variations are used in a non-exclusive manner. Thus, these terms may refer to the case where, in addition to the features introduced by these terms, no other features are present in the entity described in this context, or the case where one or more other features are present. As an example, the expressions "A has B", "A includes B" and "A contains B" may refer to the case where, in addition to B, no other elements are present in A (i.e., the case where A consists solely and exclusively of B), or the case where, in addition to B, one or more other elements (such as element C, element C and element D or even other elements) are present in entity A. The term "comprising" also covers embodiments in which only the mentioned items are present, i.e., it has a restrictive meaning in the sense of "consisting of".
[0126] Further, as used hereinafter, the terms "particularly", "more particularly", "generally" and "more generally" or similar terms are used in conjunction with additional / alternative features without limiting the possibilities of substitution. Therefore, the features introduced by these terms are additional / alternative features and are not intended to limit the scope of the claims in any way. As the skilled person will recognize, the present invention may be performed by using alternative features. Similarly, features introduced by "in an embodiment of the present invention" or similar expressions are intended to be additional / alternative features without any limitation on alternative embodiments of the present invention, without any limitation on the scope of the present invention, and without any limitation on the possibility of combining the features introduced in this manner with other additional / alternative or non-additional / alternative features of the present invention.
[0127] Further, it should be understood that the term "at least one" as used herein means that one or more of the items mentioned after the term can be used according to the present invention. For example, if the term indicates that at least one sampling unit should be used, it can be understood as one sampling unit or more than one sampling unit, that is, two, three, four, five or any other number. Depending on the item referred to by the term, the skilled person will understand the upper limit (if any) that the term can refer to.
[0128] The term "about" as used herein means that there is an interval precision that can achieve a technical effect relative to any number cited after the term. Therefore, "about" described herein preferably refers to an exact value or a range of ±20%, preferably ±15%, more preferably ±10%, or even more preferably ±5% of the exact value.
[0129] The term "subject" as used herein refers to an animal, preferably a mammal, and more typically a human. The subject to be studied by the method or use of the present invention should be suspected of suffering from a cardiac condition or should suffer from a cardiac condition. In one embodiment, the cardiac condition is myocardial infarction.
[0130] As used herein, the term "sample" refers to any sample containing the first, second and / or third biomarker described herein under physiological conditions. More typically, the sample is a body fluid sample, such as a blood sample or a sample derived therefrom (e.g., serum or plasma), a urine sample, a saliva sample, an interstitial fluid, a lymph sample, etc. In a preferred embodiment, the sample is a blood (i.e., whole blood), serum or plasma sample. Serum is the liquid fraction of whole blood obtained after blood coagulation. In order to obtain serum, blood clots are removed by centrifugation and supernatant is collected. Plasma is the fluid part without cells in blood. In order to obtain a plasma sample, whole blood is collected in a test tube (e.g., a citrate-treated test tube or an EDTA-treated test tube) treated with anticoagulation. Cells are taken out from the sample by centrifugation, and supernatant (i.e., plasma sample) is obtained.
[0131] "Percent (%) amino acid sequence identity" relative to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical to the amino acid residues in a reference polypeptide sequence after aligning the candidate sequence with the reference sequence and introducing gaps (if necessary) to achieve the maximum percentage of sequence identity. Preferably, standard parameters are applied to determine the degree of sequence identity between two sequences. Preferably, the degree of identity is determined by comparing two optimally aligned sequences in a comparison window, wherein the amino acid sequence fragment in the comparison window may contain additions or deletions (e.g., gaps or overhangs) to achieve optimal alignment compared to the reference sequence (excluding additions or deletions). The percentage is calculated by determining the number of positions of the identical amino acid residues present in the two sequences to obtain the number of matched positions, dividing the number of matched positions by the total number of positions in the comparison window and multiplying the result by 100 to obtain the percentage of sequence identity. The best sequence alignment for comparison can be by the homology alignment algorithm of Smith and Waterman (Add. APL. Math. 2: 482 (1981)), by the homology alignment algorithm of Needleman and Wunsch (J. Mol. Biol. 48: 443 (1970)), by the search similarity method of Pearson and Lipman (Proc. Natl. Acad. Sci. (USA) 85: 2444 (1988)), by computerized implementation of these algorithms (e.g., GAP, BESTFIT, BLAST, PASTA and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group (GCG), 575 Science Dr., Madison, WI), or by visual inspection. Given that two sequences have been identified for comparison, it is preferred to use GAP and BESTFIT to determine their best alignment, thereby determining the degree of identity. It is best to use the default values of 5.00 for gap weight and 0.30 for gap weight length. In one embodiment, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch algorithm (Needleman 1970, J. Mol. Biol. (48): 444-453), which has been incorporated into the needle program in the EMBOSS software package (EMBOSS: European Molecular Biology Open Software Suite, Rice, P., Longden, I. and Bleasby, A., Trends in Genetics 16(6), 276-277, 2000), the BLOSUM62 scoring matrix, and a gap opening penalty of 10 and a gap widening penalty of 0.5.A preferred non-limiting example of parameters for aligning two amino acid sequences using the needle program are the default parameters including the EBLOSUM62 scoring matrix, a gap opening penalty of 10, and a gap widening penalty of 0.5.
[0132] The term "antibody" refers to an immunoglobulin or immunoglobulin-like molecule, including, but not limited to, IgA, IgD, IgE, IgG and IgM, combinations thereof, and similar molecules produced during the immune response of any vertebrate, such as mammals such as goats, rabbits and mice, and non-mammalian species, such as shark immunoglobulins. For example, the antibody can be a rabbit antibody. The term "antibody" includes complete immunoglobulins and antibody binding fragments that specifically bind to a target molecule (or a group of highly similar target molecules) to substantially exclude binding to other molecules. The term "antibody" also includes genetically engineered forms, such as chimeric antibodies (e.g., humanized mouse antibodies) and complex conjugate antibodies (e.g., bispecific antibodies). See also Pierce Catalog and Handbook, 1994-1995 (Pierce Chemical Co., Rockford, 111.); Kuby, J., Immunology, 3rd Edition, WH Freeman & Co., New York, 1997.
[0133] In particular, the term "antibody" refers to a polypeptide ligand comprising at least a light chain and a heavy chain immunoglobulin variable region, which specifically recognizes and binds to an epitope of an antigen. Antibodies are composed of heavy chains and light chains, each of which has a variable region, referred to as a variable heavy chain (VH) region and a variable light chain (VL) region. The VH region and the VL region are jointly responsible for binding to the antigen recognized by the antibody. Typically, the antibodies of the present invention have a heavy (H) chain and a light (L) chain interconnected by disulfide bonds. As used herein, the term "light chain" includes full-length light chains and fragments thereof having sufficient variable region sequence to confer binding specificity. A full-length light chain includes the variable region domains VH and VL. L and constant region domain C L The variable region domain of the light chain is located at the amino terminus of the polypeptide. Light chains include kappa chains and lambda chains. The term "heavy chain" includes full-length heavy chains and fragments thereof that have sufficient variable region sequence to confer binding specificity. A full-length heavy chain includes the variable region domain V H and three constant region domains C H 1. C H 2 and C H 3. V H The domain is at the amino terminus of the polypeptide, C H The domain is at the carboxyl terminus, where C H 3 closest to the carboxyl terminus of the peptide,
[0134] There are five major heavy chain classes (or isotypes) that determine the functional activity of antibody molecules: IgM, IgD, IgG, IgA, and IgE. The heavy and light chains each contain a constant region and a variable region (these regions are also called "domains"). Combined together, the heavy and light chain variable regions specifically bind to antigens. The light and heavy chain variable regions contain a "framework" region interrupted by three hypervariable regions, also called a "complementarity determining region" or "CDR". The CDRs are primarily responsible for binding to antigenic epitopes. The CDRs of each chain are usually referred to as CDR1, CDR2, and CDR3, numbered sequentially from the N-terminus, and are also usually identified by the chain in which the particular CDR is located. Therefore, VH CDR3 is located in the variable domain of the heavy chain of the antibody in which it is found, while VL CDR1 is the CDR1 of the variable domain of the light chain of the antibody in which it is found. Antibodies that bind to MYBPC3 will have specific VH and VL region sequences, and thus specific CDR sequences.
[0135] The complementary determining regions (CDRs) and framework regions of a given antibody can be identified using the system described by Kabat et al. in Sequences of Proteins of Immunological Interest (5th edition, U.S. Department of Health and Human Services, PHS, NIH, NIH Publication No.: 91-3242, 1991). In the present invention, the CDR sequences were determined according to the system described by Kabat. However, the CDRs can also be redefined according to an alternative naming scheme based on the IMGT definition (Lefranc, MP et al., 2003, Dev Comp Immunol. 27 (1): 55-77).
[0136] The antibody of the present invention or its fragment can be a single-chain antibody, an IgD antibody, an IgE antibody, an IgM antibody, an IgG antibody and a fragment thereof. For example, the antibody can be an IgG antibody such as an IgG1 antibody, an IgG2 antibody, an IgG3 antibody or an IgG4 antibody. In one embodiment, the antibody or its fragment has been recombinantly produced.
[0137] The present invention also encompasses fragments of the monoclonal antibodies of the present invention. The fragment should be an immunologically functional fragment, i.e., an antigen (MYBPC3)-binding fragment. Therefore, the monoclonal antibody fragment of the present invention should be able to bind to MYBPC3, such as human MYBPC3. Therefore, as used herein, the term "immunologically functional fragment" of an antibody refers to a portion of an antibody that lacks at least some of the amino acids present in the full-length chain but is able to specifically bind to MYBPC3. Immunologically functional immunoglobulin fragments include Fab, Fab', F(ab')2 and Fv fragments. How to produce antigen-binding fragments is well known in the art. For example, fragments can be produced by enzymatic cleavage of the antibodies of the present invention. In addition, fragments can be produced by synthetic or recombinant techniques. Fab fragments are preferably produced by papain digestion of antibodies, Fab' fragments are produced by pepsin digestion and partial reduction, and F(ab')2 fragments are produced by pepsin digestion. Fv fragments are preferably produced by molecular biology techniques.
[0138] Antibody fragments may also be diabodies, which are small antibody fragments with two antigen-binding sites. Diabodies preferably comprise a heavy chain variable domain connected to a light chain variable domain in the same polypeptide chain.
[0139] The antibody of the present invention is preferably a monoclonal antibody. As used herein, the term "monoclonal antibody" refers to an antibody produced by a single B lymphocyte or by a cell transfected with the light chain and heavy chain genes of a single antibody. Monoclonal antibodies are produced by methods known to those skilled in the art (e.g., by preparing hybrid antibody-forming cells from the fusion of myeloma cells with immune spleen cells).
[0140] In embodiments, the antibody of the present invention is an isolated antibody. Therefore, the antibody should be a purified antibody. The purification of the antibody can be achieved by methods well known in the art such as size exclusion chromatography (SEC). Therefore, the antibody should be separated from the cell producing the antibody. In some embodiments, the isolated antibody is purified to an antibody greater than 70% weight as measured by, for example, the Lowry method, and in some embodiments, is purified to greater than 80%, 90%, 95%, 96%, 97%, 98% or 99% weight. In a preferred embodiment, the isolated antibody according to the present invention is purified to a purity greater than 90%, as determined by SDS-PAGE under reducing conditions using Coomassie blue staining for protein detection.
[0141] The monoclonal antibodies or fragments thereof of the present invention should specifically bind to a MYBPC3 polypeptide, such as a human MYBPC3 polypeptide. The expressions "binding" and "specifically binding" are well understood and are used to indicate that the antibody (or fragment thereof) does not significantly bind to other biomolecules.
[0142] Preferably, the antibodies (or fragments thereof) of the invention should specifically bind to the natively folded MYBPC3 protein. In particular, they should recognize a non-linear conformational epitope presented by the natively folded MYBPC3 protein. The amino acid residues contained in the conformational epitopes of antibodies 7B5 and M-4.1.1 are shown in Tables 7 and 8, respectively. The epitope is present in the N-terminal portion of the MYBPC3 protein. The epitope region is also highlighted in Fig.13 and 14 Typically, the antibodies of the present invention bind to the epitope regions shown in the above tables and figures.
[0143] The term "epitope" refers to a protein determinant that can specifically bind to an antibody. Therefore, the term preferably refers to a portion of a MYBPC3 polypeptide (e.g., a human MYBPC3 polypeptide) that can be specifically bound by an antibody (or fragment thereof) of the present invention. An epitope is generally composed of a large group of chemically active surfaces of molecules such as amino acids, and generally an epitope has specific three-dimensional structural characteristics and specific charge characteristics.
[0144] In a preferred embodiment, the antibody of the present invention or its fragment is connected to a detectable marker. Detectable markers as described herein are preferably non-naturally attached to the antibody or its antigen-binding fragment. Therefore, the detectable marker is preferably heterologous to the antibody. Suitable labels are any labels that can be detected by suitable detection methods. In one embodiment, the detectable marker is an enzyme, biotin, a radioactive label, a fluorescent label, a chemiluminescent label, an electrochemiluminescent label, a gold label or a magnetic label.
[0145] Enzyme labels include, for example, horseradish peroxidase, alkaline phosphatase, beta-galactosidase, and luciferase. Substrates for these enzymes are well known in the art. Suitable substrates for detection include diaminobenzidine (DAB), 3,3'-5,5'-tetramethylbenzidine, NBT-BCIP (4-nitro blue tetrazolium chloride and 5-bromo-4-chloro-3-indolyl phosphate). Suitable enzyme-substrate combinations can produce colored reaction products, fluorescence or chemiluminescence, which can be measured according to methods known in the art. Fluorescent labels, for example, include 5-carboxyfluorescein, fluorescein isothiocyanate, rhodamine, tetramethylrhodamine, Cy2, Cy3, and Cy5, fluorescent proteins such as GFP (green fluorescent protein), Texas Red, and Alexa dyes. Radioactive labels, for example, include radioactive isotopes of iodide, cobalt, selenium, tritium, carbon, sulfur, and phosphorus. Radioactive labels can be detected by any known and appropriate method, such as photographic film or phosphorimager. Magnetic labels, for example, include paramagnetic and superparamagnetic labels. Chemiluminescent labels used may include luminol, isoluminol, aromatic acridinium esters, imidazoles, acridinium salts or oxalate esters.
[0146] The present invention further relates to host cells producing antibodies of the present invention or their antigen-binding fragments. In a preferred embodiment, the host producing antibodies of the present invention is a hybridoma cell. In addition, the host cell can be any type of cell system, which can be engineered to produce antibodies according to the present invention. For example, the host cell can be an animal cell, particularly a mammalian cell. In one embodiment, HEK293 (human embryonic kidney cell) such as the HEK293-F cell used in the embodiment section, or CHO (Chinese hamster ovary) cell is used as a host cell. In another embodiment, the host cell is a non-human animal or a mammalian cell.
[0147] The host cell preferably comprises at least one polynucleotide encoding an antibody of the present invention or a fragment thereof. For example, the host cell comprises at least one polynucleotide encoding an antibody light chain of the present invention and at least one polynucleotide encoding an antibody heavy chain of the present invention. The one or more polynucleotides should be operably linked to a suitable promoter.
[0148] The definitions and explanations given above preferably apply mutatis mutandis to the following.
[0149] The antibodies or antigen-binding fragments thereof of the invention can be used in methods related to the localization and / or quantification of MYBPC3 polypeptides. For example, the antibodies or fragments thereof allow the amount of MYBPC3 polypeptides in a sample to be determined, for use in diagnostic methods, or for imaging MYBPC3 polypeptides.
[0150] Therefore, the present invention relates to the in vitro use of the monoclonal antibody or fragment thereof of the present invention, or the kit of the present invention for the detection of MYBPC3 (i.e., MYBPC3 polypeptide) in a sample. In one embodiment, the detection is a quantitative detection. Typically, the sample is a body fluid, such as a blood, serum or plasma sample. Typically, the sample is derived from a subject described elsewhere herein.
[0151] Furthermore, the present invention relates to a method for detecting MYBPC3 in a sample, the method comprising
[0152] (a) contacting a sample containing MYBPC3 with a first and / or second monoclonal antibody or a fragment thereof of the present invention, thereby forming a complex comprising MYBPC3 and the monoclonal antibody (or two monoclonal antibodies) or a fragment thereof, and
[0153] (b) detecting the complex formed in step (a), thereby detecting MYBPC3 in the sample.
[0154] Preferably, the detecting is determining the amount of MYBPC3 in a sample.
[0155] Preferably, the sample in step a) of the above method is contacted with the first and second monoclonal antibodies or fragments thereof of the present invention, thereby forming a complex comprising MYBPC3 and the two monoclonal antibodies or antigen-binding fragments thereof.
[0156] For the detection of MYBPC3 described herein, various immunoassay techniques in such assay formats can be used, see, for example, U.S. Pat. Nos. 4,016,043, 4,424,279, and 4,018,653. These techniques include single-site and two-site or "sandwich" assays of non-competitive type, as well as traditional competitive binding assays. These assays also include direct binding of labeled antibodies to target biomarkers.
[0157] Preferably, the detection is based on electrochemiluminescence. Methods employing electrochemiluminescent labels are well known. Such methods utilize the ability of a special metal complex to achieve an excited state by oxidation, from which the special metal complex decays to a ground state, thereby emitting electrochemiluminescence. For a review, see Richter, MM, Chem. Rev. 2004; 104: 3003-3036. Typically, electrochemiluminescent immunoassays are performed via an electrochemiluminescent immunoassay (ECLIA) that works by the sandwich principle. A first biotinylated monoclonal antibody or a fragment thereof (such as a F(ab')2-fragment of a first antibody) and a ruthenium-containing second monoclonal antibody form a sandwich immunoassay complex with MYBPC3 in the sample. The complex is then bound to solid phase streptavidin-coated microparticles. These are magnetically captured on the electrode surface, resulting in chemiluminescent emission when a voltage is applied to the electrode, which is measured by a photomultiplier tube.
[0158] In one embodiment of a sandwich assay for the determination of MYBPC3, the assay comprises a biotinylated first monoclonal antibody (or a fragment thereof) and a ruthenium-ylated second monoclonal antibody (or a fragment thereof). Both antibodies form a sandwich immunoassay complex with MYBPC3 present in the sample.
[0159] Thus, it is envisaged that a first monoclonal antibody or fragment thereof (such as a F(ab')2-fragment) is biotinylated and a second monoclonal antibody or fragment thereof is ruthenylated.
[0160] The present invention further relates to the use of a monoclonal antibody or fragment thereof, in particular two antibodies (e.g., in the form of a sandwich assay) of the present invention for diagnostic assessment in a sample from a subject. Preferably, the antibody (or fragment thereof) or sandwich assay is used to determine the amount of a biomarker. The determined amount can then be used for diagnostic assessment.
[0161] In a preferred embodiment, cardiac symptoms are assessed.
[0162] The present invention further relates to the in vitro use of the monoclonal antibody or fragment thereof of the present invention, or the kit of the present invention for assessing cardiac symptoms.
[0163] Similarly, the present invention relates to a method for assessing a cardiac condition in a subject, the method comprising
[0164] (a) determining the amount of the biomarker MYBPC3 in a sample from the subject,
[0165] (b) comparing the amount of the biomarker to a reference amount used to assess cardiac symptoms; and
[0166] (c) assessing the cardiac condition based on the comparison made in step (b).
[0167] In a preferred embodiment, the cardiac condition to be assessed is heart failure. Preferably, the assessment of the cardiac condition is a diagnosis of heart failure in a subject suffering from heart failure.
[0168] In another preferred embodiment, the cardiac condition to be assessed is myocardial damage.
[0169] In another preferred embodiment, the cardiac condition to be assessed is myocardial infarction.
[0170] In a preferred embodiment, the assessment of myocardial infarction is a diagnosis of myocardial infarction. In particular, the assessment of myocardial infarction is a exclusion of myocardial infarction. Typically, the subject to be tested is a subject suspected of having myocardial infarction.
[0171] In another preferred embodiment, the assessment of myocardial infarction is to differentiate between type 1 and type 2 myocardial infarction.
[0172] In another preferred embodiment, the assessment of myocardial infarction is a prediction of the risk of myocardial infarction and / or cardiac death within a certain number of days for a patient suspected of having myocardial infarction, for example, predicting the risk within 30 days (and thus within 30 days).
[0173] The term "type 1 myocardial infarction" is well known in the art. As used herein, the term refers to an AMI with a potential ischemic cause of atherosclerotic plaque rupture / erosion and occlusive or non-occlusive thrombus formation in one or more coronary arteries. Therefore, the criteria for type 1 AMI include the previously mentioned AMI criteria, including, for example, identification of coronary thrombus by angiography (including intracoronary imaging) or autopsy as evidence of acute myocardial ischemia (Thygesen et al., Eur J Heart 2019: 40 (3); 237-269, DOI: 10.1093 / eurheartj / ehy462).
[0174] The term "type 2 myocardial infarction" is well known in the art. As used herein, the term refers to an AMI with a potential ischemic cause of impaired oxygen supply and demand balance due to a) increased oxygen demand (e.g., sustained tachyarrhythmia or severe hypertension) or b) due to reduced oxygen supply (e.g., hypotension, bradycardia, respiratory failure, severe anemia, coronary vasospasm, coronary artery dissection or microvascular dysfunction). Therefore, the criteria for type 2 AMI include the previously mentioned AMI criteria, including evidence of imbalance between myocardial oxygen supply and demand unrelated to acute atherothrombosis (Thygesen et al., Eur J Heart 2019: 40 (3); 237-269, DOI: 10.1093 / eurheartj / ehy462).
[0175] In the following, preferred embodiments of the present invention are summarized.The definitions and explanations provided above preferably apply mutatis mutandis.
[0176] 1. A monoclonal antibody or fragment thereof that binds to MYBPC3 (myosin binding protein C, cardiac type), wherein the monoclonal antibody or fragment thereof is selected from
[0177] i) a first monoclonal antibody or a fragment thereof comprising a first light chain variable domain and / or a first heavy chain variable domain,
[0178] (a) the first light chain variable domain comprises
[0179] (a1) a first light chain CDR1 that differs from the first light chain CDR1 having the amino acid sequence shown in SEQ ID NO:1 (QASQSIGNALA) by no more than a total of three amino acid additions, substitutions and / or deletions,
[0180] (a2) a first light chain CDR2 that differs from the first light chain CDR2 having the amino acid sequence shown in SEQ ID NO:2 (STSYLPS) by no more than a total of three amino acid additions, substitutions and / or deletions, and / or
[0181] (a3) a first light chain CDR3 that differs from the first light chain CDR3 having the amino acid sequence shown in SEQ ID NO: 3 (QSYYVSTSSSDRSS) by no more than a total of three amino acid additions, substitutions and / or deletions,
[0182] (b) the first heavy chain variable domain comprises
[0183] (b1) a first heavy chain CDR1 that differs from the first heavy chain CDR1 having the amino acid sequence shown in SEQ ID NO:4 (SGYDMC) by no more than a total of three amino acid additions, substitutions and / or deletions,
[0184] (b2) the first heavy chain CDR2, which has SEQ ID NO: 5
[0185] The first heavy chain CDR2 of the amino acid sequence shown in (CIGSSSASTWYANWVNG) differs by no more than a total of three amino acid additions, substitutions and / or deletions, and / or
[0186] (b3) a first heavy chain CDR3 that differs from the first heavy chain CDR3 having the amino acid sequence shown in SEQ ID NO:6 (ESSTEYYYNL) by no more than a total of three amino acid additions, substitutions and / or deletions,
[0187] or
[0188] ii) a second monoclonal antibody or a fragment thereof comprising a second light chain variable domain and / or a second heavy chain variable domain,
[0189] (a) the second light chain variable domain comprises
[0190] (a1) a second light chain CDR1 that differs from the second light chain CDR1 having the amino acid sequence shown in SEQ ID NO:9 (RASQNIGTNMH) by no more than a total of three amino acid additions, substitutions and / or deletions,
[0191] (a2) a second light chain CDR2 that differs from the second light chain CDR2 having the amino acid sequence set forth in SEQ ID NO: 10 (FASESFS) by no more than a total of three amino acid additions, substitutions and / or deletions, and / or
[0192] (a3) a second light chain CDR3 that differs from the second light chain CDR3 having the amino acid sequence shown in SEQ ID NO: 11 (QQSYNWPFT) by no more than a total of three amino acid additions, substitutions and / or deletions,
[0193] (b) the second heavy chain variable domain comprises
[0194] (b1) a second heavy chain CDR1 that differs from the second heavy chain CDR1 having the amino acid sequence shown in SEQ ID NO: 12 (GYGVN) by no more than a total of three amino acid additions, substitutions and / or deletions,
[0195] (b2) a second heavy chain CDR2 that differs from the second heavy chain CDR2 having the amino acid sequence shown in SEQ ID NO: 13 (MIWGDGSTDYNSVYKS) by no more than a total of three amino acid additions, substitutions and / or deletions, and / or
[0196] (b3) a second heavy chain CDR3 that differs from the second heavy chain CDR3 having the amino acid sequence shown in SEQ ID NO: 14 (RDTGGASMDY) by no more than a total of three amino acid additions, substitutions and / or deletions.
[0197] 2. The monoclonal antibody or fragment thereof according to embodiment 1, wherein
[0198] i) the first light chain variable domain is at least 85%, such as at least 90% or at least 95% identical to the light chain variable domain having the sequence shown in SEQ ID NO:7 (DIVMTQTPASVEAAVGGTVTIKCQASQSIGNALAWYQQKPGQPPKLLIY STSYLPSGVPSRFKGGGSGAEYTLTISDLECADAATYYCQSYYVSTSSSDRSSFGGGTEVVVK), and wherein the first heavy chain variable domain is at least 85%, such as at least 90% or at least 95% identical to the heavy chain variable domain having the sequence shown in SEQ ID NO:8 (QEQLEESGGGLVKPGGTLTLTCKVSGFDFSSGYDMC WVRQAPGKGLESIA CIGSSSASTWYANWVNGRFTVSRSTSLNTVDLKMTSLTVADTATYFCAR ESSTEYYYNLWGPGTLVTVSS),
[0199] or
[0200] ii) the second light chain variable domain is at least 85%, such as at least 90% or at least 95% identical to the light chain variable domain having the sequence shown in SEQ ID NO:15 (DILMTQSPAILSVSPGERVSFSCRASQNIGTNMHWYQQRTNGSPRLLIR FASESFSGIPSRFSGTGSGTDFTLRINSVESEDIADYYCQQSYNWPFTFGAGTKLELK), and wherein the second heavy chain variable domain is at least 85%, such as at least 90% or at least 95% identical to the heavy chain variable domain having the sequence shown in SEQ ID NO:16 (QVQLKESGPGLVAPSQSLSITCTVSGFSLT GYGVNWVRQPPGKGLEWLG MIWGDGSTDYNSVYKSRLSISKDNSKSQVFLKMNSLQTDDTARYYCAR RDTGGASMDYWGQGTSVTVSS).
[0201] 3. The monoclonal antibody or fragment according to embodiment 1 or 2, wherein
[0202] i) the first light chain variable domain comprises the sequence shown in SEQ ID NO:7 and the first heavy chain variable domain comprises the sequence shown in SEQ ID NO:8,
[0203] ii) the second light chain variable domain comprises the sequence shown in SEQ ID NO:15 and the second heavy chain variable domain comprises the sequence shown in SEQ ID NO:16.
[0204] 4. The monoclonal antibody or fragment thereof according to any one of embodiments 1 to 3, wherein
[0205] i) the first monoclonal antibody or fragment thereof comprises
[0206] (a) a first light chain variable domain comprising
[0207] (a1) a first light chain CDR1 that differs from the first light chain CDR1 having the amino acid sequence shown in SEQ ID NO:4 (QASQSIGNALA) by no more than one amino acid addition, substitution or deletion,
[0208] (a2) a first light chain CDR2 that differs from the first light chain CDR2 having the amino acid sequence shown in SEQ ID NO:5 (STSYLPS) by no more than one amino acid addition, substitution or deletion, and / or
[0209] (a3) a first light chain CDR3 that differs from the first light chain CDR3 having the amino acid sequence shown in SEQ ID NO:6 (QSYYVSTSSSDRSS) by no more than one amino acid addition, substitution or deletion,
[0210] (b) a first heavy chain variable domain comprising
[0211] (b1) a first heavy chain CDR1 that differs from the first heavy chain CDR1 having the amino acid sequence shown in SEQ ID NO:7 (SGYDMC) by no more than one amino acid addition, substitution or deletion,
[0212] (b2) a first heavy chain CDR2 that differs from the first heavy chain CDR2 having the amino acid sequence shown in SEQ ID NO:8 (CIGSSSASTWYANWVNG) by no more than one amino acid addition, substitution or deletion, and / or
[0213] (b3) a first heavy chain CDR3 that differs from the first heavy chain CDR3 having the amino acid sequence shown in SEQ ID NO:9 (ESSTEYYYNL) by no more than one amino acid addition, substitution or deletion,
[0214] ii) the second monoclonal antibody or fragment thereof comprises
[0215] (a) a second light chain variable domain comprising
[0216] (a1) a second light chain CDR1 that differs from a second light chain CDR1 having an amino acid sequence as shown in SEQ ID NO:9 (RASQNIGTNMH) by no more than one amino acid addition, substitution or deletion,
[0217] (a2) a second light chain CDR2 that differs from the second light chain CDR2 having the amino acid sequence shown in SEQ ID NO: 10 (FASESFS) by no more than one amino acid addition, substitution or deletion, and / or
[0218] (a3) a second light chain CDR3 that differs from the second light chain CDR3 having the amino acid sequence shown in SEQ ID NO: 11 (QQSYNWPFT) by no more than one amino acid addition, substitution or deletion,
[0219] (b) a second heavy chain variable domain comprising
[0220] (b1) a second heavy chain CDR1 that differs from the second heavy chain CDR1 having the amino acid sequence shown in SEQ ID NO: 12 (GYGVN) by no more than one amino acid addition, substitution or deletion,
[0221] (b2) a second heavy chain CDR2 that differs from the second heavy chain CDR2 having the amino acid sequence shown in SEQ ID NO: 13 (MIWGDGSTDYNSVYKS) by no more than one amino acid addition, substitution or deletion, and / or
[0222] (b3) a second heavy chain CDR3 that differs from the second heavy chain CDR3 having the amino acid sequence shown in SEQ ID NO: 14 (RDTGGASMDY) by no more than one amino acid addition, substitution or deletion.
[0223] 5. The monoclonal antibody or fragment thereof according to any one of embodiments 1 to 4, wherein
[0224] i) the first monoclonal antibody or fragment thereof comprises
[0225] (a) a first light chain variable domain comprising
[0226] (a1) a first light chain CDR1 having the sequence shown in SEQ ID NO: 1 (QASQSIGNALA),
[0227] (a2) a first light chain CDR2 having the sequence shown in SEQ ID NO: 2 (STSYLPS), and
[0228] (a3) a first light chain CDR3 having the sequence shown in SEQ ID NO: 3 (QSYYVSTSSSDRSS),
[0229] as well as
[0230] (b) a first heavy chain variable domain comprising
[0231] (b1) a first heavy chain CDR1 having the sequence shown in SEQ ID NO:4 (SGYDMC),
[0232] (b2) a first heavy chain CDR2 having the sequence shown in SEQ ID NO:5 (CIGSSSASTWYANWVNG), and
[0233] (b3) a first heavy chain CDR3 having the sequence shown in SEQ ID NO:6 (ESSTEYYYNL),
[0234] ii) the second monoclonal antibody or fragment thereof comprises
[0235] (a) a second light chain variable domain comprising
[0236] (a1) a second light chain CDR1 having the sequence shown in SEQ ID NO:9 (RASQNIGTNMH),
[0237] (a2) a second light chain CDR2 having the sequence shown in SEQ ID NO: 10 (FASESFS), and
[0238] (a3) a second light chain CDR3 having the sequence shown in SEQ ID NO: 11 (QQSYNWPFT),
[0239] as well as
[0240] (b) a second heavy chain variable domain comprising
[0241] (b1) a second heavy chain CDR1 having the sequence shown in SEQ ID NO: 12 (GYGVN),
[0242] (b2) a second heavy chain CDR2 having the sequence shown in SEQ ID NO: 13 (MIWGDGSTDYNSVYKS), and
[0243] (b3) The second heavy chain CDR3 has the sequence shown in SEQ ID NO: 14 (RDTGGASMDY).
[0244] 6. The monoclonal antibody or fragment thereof according to any one of embodiments 1 to 5, wherein the first antibody or fragment thereof, and / or the second antibody or fragment thereof is labeled, and / or wherein the fragment is a Fab fragment, a Fab' fragment, a Facb fragment, a F(ab')2 fragment, a scFv fragment or a Fv fragment, in particular, wherein the fragment is a F(ab')2 fragment.
[0245] 7. A kit comprising i) a first antibody or a fragment thereof as defined in any one of the preceding embodiments, and ii) a second antibody or a fragment thereof as defined in any one of the preceding embodiments.
[0246] 8. The kit according to embodiment 7, wherein the kit comprises a biotinylated F(ab')2 fragment of a first monoclonal antibody and a second monoclonal antibody, preferably, wherein the second antibody is ruthenium-ylated.
[0247] 9. In vitro use of the monoclonal antibody or fragment thereof according to any one of embodiments 1 to 6, or the kit according to embodiment 7 or 8 for the detection of MYBPC3 in a sample.
[0248] 10. The in vitro use according to embodiment 9, wherein the detection is a quantitative detection.
[0249] 11. The in vitro use according to embodiment 9 or 10, wherein the sample is a body fluid, such as a blood, serum or plasma sample.
[0250] 12. A method for detecting MYBPC3 in a sample, the method comprising
[0251] (a) contacting a sample comprising MYBPC3 with a first and / or second monoclonal antibody or a fragment thereof according to any one of embodiments 1 to 6, thereby forming a complex comprising MYBPC3 and the monoclonal antibody or a fragment thereof, and
[0252] (b) detecting the complex formed in step (a), thereby detecting MYBPC3 in the sample.
[0253] 13. A composite comprising
[0254] i) MYBPC3, and
[0255] ii) the first monoclonal antibody or fragment thereof and / or the second monoclonal antibody or fragment thereof according to any one of embodiments 1 to 6.
[0256] 14. Use of the monoclonal antibody or fragment thereof according to any one of embodiments 1 to 6 or the kit according to claim 7 or 8 for assessing cardiac symptoms in vitro.
[0257] 15. The in vitro use according to embodiment 14, wherein the cardiac condition is heart failure.
[0258] 16. The in vitro use according to embodiment 14, wherein the cardiac condition is myocardial damage or myocardial infarction.
[0259] 17. The in vitro use according to embodiment 16, wherein the cardiac condition is myocardial infarction.
[0260] 18. The in vitro use according to embodiment 17, wherein myocardial infarction is excluded.
[0261] 19. The in vitro use according to embodiment 17, wherein type 1 and type 2 myocardial infarction are differentiated.
[0262] 20. The in vitro use according to embodiment 17, wherein the risk of myocardial infarction and / or cardiac death in a patient suspected of having acute coronary syndrome (ACS), such as the risk at 30 days, is predicted.
[0263] This article also discloses but is not limited to the following embodiments:
[0264] 1. A monoclonal antibody or fragment thereof that binds to MYBPC3 (myosin binding protein C, cardiac type), wherein the monoclonal antibody or fragment thereof is selected from
[0265] i) a first monoclonal antibody or a fragment thereof comprising a first light chain variable domain and / or a first heavy chain variable domain,
[0266] (a) the first light chain variable domain comprises
[0267] (a1) a first light chain CDR1 that differs from the first light chain CDR1 having the amino acid sequence shown in SEQ ID NO:1 (QASQSIGNALA) by no more than a total of three amino acid additions, substitutions and / or deletions,
[0268] (a2) a first light chain CDR2 that differs from the first light chain CDR2 having the amino acid sequence shown in SEQ ID NO:2 (STSYLPS) by no more than a total of three amino acid additions, substitutions and / or deletions, and / or
[0269] (a3) a first light chain CDR3 that differs from the first light chain CDR3 having the amino acid sequence shown in SEQ ID NO: 3 (QSYYVSTSSSDRSS) by no more than a total of three amino acid additions, substitutions and / or deletions,
[0270] (b) the first heavy chain variable domain comprises
[0271] (b1) a first heavy chain CDR1 that differs from the first heavy chain CDR1 having the amino acid sequence shown in SEQ ID NO:4 (SGYDMC) by no more than a total of three amino acid additions, substitutions and / or deletions,
[0272] (b2) a first heavy chain CDR2 that differs from the first heavy chain CDR2 having the amino acid sequence shown in SEQ ID NO:5 (CIGSSSASTWYANWVNG) by no more than a total of three amino acid additions, substitutions and / or deletions, and / or
[0273] (b3) a first heavy chain CDR3 that differs from the first heavy chain CDR3 having the amino acid sequence shown in SEQ ID NO:6 (ESSTEYYYNL) by no more than a total of three amino acid additions, substitutions and / or deletions,
[0274] or
[0275] ii) a second monoclonal antibody or a fragment thereof comprising a second light chain variable domain and / or a second heavy chain variable domain,
[0276] (a) the second light chain variable domain comprises
[0277] (a1) a second light chain CDR1 that differs from the second light chain CDR1 having the amino acid sequence shown in SEQ ID NO:9 (RASQNIGTNMH) by no more than a total of three amino acid additions, substitutions and / or deletions,
[0278] (a2) a second light chain CDR2 that differs from the second light chain CDR2 having the amino acid sequence set forth in SEQ ID NO: 10 (FASESFS) by no more than a total of three amino acid additions, substitutions and / or deletions, and / or
[0279] (a3) a second light chain CDR3 that differs from the second light chain CDR3 having the amino acid sequence shown in SEQ ID NO: 11 (QQSYNWPFT) by no more than a total of three amino acid additions, substitutions and / or deletions,
[0280] (b) the second heavy chain variable domain comprises
[0281] (b1) a second heavy chain CDR1 that differs from the second heavy chain CDR1 having the amino acid sequence shown in SEQ ID NO: 12 (GYGVN) by no more than a total of three amino acid additions, substitutions and / or deletions,
[0282] (b2) a second heavy chain CDR2 that differs from the second heavy chain CDR2 having the amino acid sequence shown in SEQ ID NO: 13 (MIWGDGSTDYNSVYKS) by no more than a total of three amino acid additions, substitutions and / or deletions, and / or
[0283] (b3) a second heavy chain CDR3 that differs from the second heavy chain CDR3 having the amino acid sequence shown in SEQ ID NO: 14 (RDTGGASMDY) by no more than a total of three amino acid additions, substitutions and / or deletions.
[0284] 2. The monoclonal antibody or fragment thereof according to embodiment 1, wherein
[0285] The first light chain variable domain is at least 85%, such as at least 90% or at least 95% identical to the light chain variable domain having the sequence shown in SEQ ID NO:7 (DIVMTQTPASVEAAVGGTVTIKCQASQSIGNALAWYQQKPGQPPKLLIY STSYLPSGVPSRFKGGGSGAEYTLTISDLECADAATYYCQSYYVSTSSSDRSS FGGGTEVVVK), and
[0286] The first heavy chain variable domain is at least 85%, such as at least 90% or at least 95% identical to the heavy chain variable domain having the sequence shown in SEQ ID NO:8 (QEQLEESGGGLVKPGGTLTLTCKVSGFDFS SGYDMCWVRQAPGKGLESIA CIGSSSASTWYANWVNGRFTVSRSTSLNTVDLKMTSLTVADTATYFCAR ESSTEYYYNLWGPGTLVTVSS),
[0287] or
[0288] The second light chain variable domain is at least 85%, such as at least 90% or at least 95% identical to the light chain variable domain having the sequence shown in SEQ ID NO: 15 (DILMTQSPAILSVSPGERVSFSCRASQNIGTNMHWYQQRTNGSPRLLIR FASESFSGIPSRFSGTGSGTDFTLRINSVESEDIADYYCQQSYNWPFTFGAGTKLELK), and
[0289] The second heavy chain variable domain is at least 85%, such as at least 90% or at least 95% identical to the heavy chain variable domain having the sequence shown in SEQ ID NO: 16 (QVQLKESGPGLVAPSQSLSITCTVSGFSLT GYGVNWVRQPPGKGLEWLG MIWGDGSTDYNSVYKSRLSISKDNSKSQVFLKMNSLQTDDTARYYCARRDTGGASMDY WGQGTSVTVSS).
[0290] 3. The monoclonal antibody or fragment according to embodiment 1 or 2, wherein
[0291] i) the first light chain variable domain comprises the sequence shown in SEQ ID NO:7 and the first heavy chain variable domain comprises the sequence shown in SEQ ID NO:8,
[0292] ii) the second light chain variable domain comprises the sequence shown in SEQ ID NO:15 and the second heavy chain variable domain comprises the sequence shown in SEQ ID NO:16.
[0293] 4. The monoclonal antibody or fragment thereof according to any one of embodiments 1 to 3, wherein
[0294] i) the first monoclonal antibody or fragment thereof comprises
[0295] (a) a first light chain variable domain comprising
[0296] (a1) a first light chain CDR1 that differs from the first light chain CDR1 having the amino acid sequence shown in SEQ ID NO:4 (QASQSIGNALA) by no more than one amino acid addition, substitution or deletion,
[0297] (a2) a first light chain CDR2 that differs from the first light chain CDR2 having the amino acid sequence shown in SEQ ID NO:5 (STSYLPS) by no more than one amino acid addition, substitution or deletion, and / or
[0298] (a3) a first light chain CDR3 that differs from the first light chain CDR3 having the amino acid sequence shown in SEQ ID NO:6 (QSYYVSTSSSDRSS) by no more than one amino acid addition, substitution or deletion,
[0299] (b) a first heavy chain variable domain comprising
[0300] (b1) a first heavy chain CDR1 that differs from the first heavy chain CDR1 having the amino acid sequence shown in SEQ ID NO:7 (SGYDMC) by no more than one amino acid addition, substitution or deletion,
[0301] (b2) a first heavy chain CDR2 that differs from the first heavy chain CDR2 having the amino acid sequence shown in SEQ ID NO:8 (CIGSSSASTWYANWVNG) by no more than one amino acid addition, substitution or deletion, and / or
[0302] (b3) a first heavy chain CDR3 that differs from the first heavy chain CDR3 having the amino acid sequence shown in SEQ ID NO:9 (ESSTEYYYNL) by no more than one amino acid addition, substitution or deletion,
[0303] ii) the second monoclonal antibody or fragment thereof comprises
[0304] (a) a second light chain variable domain comprising
[0305] (a1) a second light chain CDR1 that differs from a second light chain CDR1 having an amino acid sequence as shown in SEQ ID NO:9 (RASQNIGTNMH) by no more than one amino acid addition, substitution or deletion,
[0306] (a2) a second light chain CDR2 that differs from the second light chain CDR2 having the amino acid sequence shown in SEQ ID NO: 10 (FASESFS) by no more than one amino acid addition, substitution or deletion, and / or
[0307] (a3) a second light chain CDR3 that differs from the second light chain CDR3 having the amino acid sequence shown in SEQ ID NO: 11 (QQSYNWPFT) by no more than one amino acid addition, substitution or deletion,
[0308] (b) a second heavy chain variable domain comprising
[0309] (b1) a second heavy chain CDR1 that differs from the second heavy chain CDR1 having the amino acid sequence shown in SEQ ID NO: 12 (GYGVN) by no more than one amino acid addition, substitution or deletion,
[0310] (b2) a second heavy chain CDR2 that differs from the second heavy chain CDR2 having the amino acid sequence shown in SEQ ID NO: 13 (MIWGDGSTDYNSVYKS) by no more than one amino acid addition, substitution or deletion, and / or
[0311] (b3) a second heavy chain CDR3 that differs from the second heavy chain CDR3 having the amino acid sequence shown in SEQ ID NO: 14 (RDTGGASMDY) by no more than one amino acid addition, substitution or deletion.
[0312] 5. The monoclonal antibody or fragment thereof according to any one of embodiments 1 to 4, wherein
[0313] i) the first monoclonal antibody or fragment thereof comprises
[0314] (a) a first light chain variable domain comprising
[0315] (a1) the first light chain CDR1 has the sequence shown in SEQ ID NO: 1 (QASQSIGNALA),
[0316] (a2) the first light chain CDR2 has the sequence shown in SEQ ID NO: 2 (STSYLPS), and
[0317] (a3) the first light chain CDR3 has the sequence shown in SEQ ID NO: 3 (QSYYVSTSSSDRSS), and
[0318] (b) a first heavy chain variable domain comprising
[0319] (b1) a first heavy chain CDR1 having the sequence shown in SEQ ID NO:4 (SGYDMC),
[0320] (b2) a first heavy chain CDR2 having the sequence shown in SEQ ID NO:5 (CIGSSSASTWYANWVNG), and
[0321] (b3) a first heavy chain CDR3 having the sequence shown in SEQ ID NO:6 (ESSTEYYYNL),
[0322] ii) the second monoclonal antibody or fragment thereof comprises
[0323] (a) a second light chain variable domain comprising
[0324] (a1) a second light chain CDR1 having the sequence shown in SEQ ID NO:9 (RASQNIGTNMH),
[0325] (a2) a second light chain CDR2 having the sequence shown in SEQ ID NO: 10 (FASESFS), and
[0326] (a3) a second light chain CDR3 having the sequence shown in SEQ ID NO: 11 (QQSYNWPFT),
[0327] as well as
[0328] (b) a second heavy chain variable domain comprising
[0329] (b1) a second heavy chain CDR1 having the sequence shown in SEQ ID NO: 12 (GYGVN),
[0330] (b2) a second heavy chain CDR2 having the sequence shown in SEQ ID NO: 13 (MIWGDGSTDYNSVYKS), and
[0331] (b3) The second heavy chain CDR3 has the sequence shown in SEQ ID NO: 14 (RDTGGASMDY).
[0332] 6. A monoclonal antibody or fragment thereof according to any one of embodiments 1 to 5, wherein the first antibody or fragment thereof, and / or the second antibody or fragment thereof is labeled, and / or wherein the fragment is a Fab fragment, a Fab' fragment, a Facb fragment, a F(ab')2 fragment, a scFv fragment or a Fv fragment, in particular, wherein the fragment is a F(ab')2 fragment.
[0333] 7. A kit comprising
[0334] i) a first antibody or a fragment thereof as defined in any one of the preceding embodiments, and
[0335] ii) a second antibody or fragment thereof as defined in any of the preceding embodiments.
[0336] 8. The kit according to embodiment 7, wherein the kit comprises i) a biotinylated F(ab')2 fragment of the first monoclonal antibody and ii) the second monoclonal antibody, preferably, wherein the second antibody is ruthenium-ylated.
[0337] 9. In vitro use of the monoclonal antibody or fragment thereof according to any one of embodiments 1 to 6, or the kit according to embodiment 7 or 8 for the detection of MYBPC3 in a sample, for example, wherein the detection is a quantitative detection.
[0338] 10. The in vitro use according to embodiment 9, wherein the sample is a body fluid, such as a blood, serum or plasma sample.
[0339] 11. A method for detecting MYBPC3 in a sample, the method comprising
[0340] (a) contacting a sample comprising MYBPC3 with a first and / or second monoclonal antibody or a fragment thereof according to any one of embodiments 1 to 6, thereby forming a complex comprising MYBPC3 and the monoclonal antibody or a fragment thereof, and
[0341] (b) detecting the complex formed in step (a), thereby detecting MYBPC3 in the sample.
[0342] 12. A composite comprising
[0343] i) MYBPC3, and
[0344] ii) the first monoclonal antibody or fragment thereof, and / or the second monoclonal antibody or fragment thereof according to any one of embodiments 1 to 6.
[0345] 13. In vitro use of the monoclonal antibody or fragment thereof according to any one of embodiments 1 to 6, or the kit according to embodiment 7 or 8 for assessing cardiac symptoms.
[0346] 14. The in vitro use according to embodiment 13, wherein the cardiac condition is heart failure, or wherein the cardiac condition is myocardial damage or myocardial infarction.
[0347] 15. The in vitro use according to embodiment 14, wherein the cardiac condition is myocardial infarction, and wherein
[0348] ● Rule out myocardial infarction,
[0349] ● Differentiate between type 1 and type 2 myocardial infarction, and / or
[0350] ●Predict the risk of myocardial infarction and / or cardiac death in patients suspected of having an acute coronary syndrome (ACS), for example, at 30 days.
[0351] All patents, patent applications, and publications or disclosures mentioned or cited herein are incorporated by reference in their entirety.
[0352] The present invention will be further described with reference to the examples described herein; however, it should be understood that the present invention is not limited to such examples.
[0353] Example 1: Immunogen
[0354] Recombinant expression of MYBPC3
[0355] Full-length human cardiac myosin binding protein C3 (Uniprot Q14896) is a large and difficult to express protein (data not shown).
[0356] In contrast, N-terminal residues 1 to 330 of Uniprot Q14896 were fused to a C-terminal His tag for purification, resulting in soluble and reproducible expression in human embryonic kidney (HEK) 293 cells.
[0357] The 330 N-terminal residues including the C-terminal His tag are shown in SEQ ID NO: 17:
[0358]
[0359] SEQ ID NO: 18 shows the amino acid sequence without the His tag:
[0360]
[0361]
[0362] 301KRDSFRTPRDSKLEAPAEED VWEILRQAPP(SEQ ID NO:18)
[0363] All expression plasmids have the human cytomegalovirus immediate early enhancer / promoter region, and the coding gene region is followed by the bovine growth hormone polyadenylation signal.
[0364] For transient gene expression, use FreeStyle TM 293-F Expression System (Thermo Fischer Scientific): According to the manufacturer's instructions, cultures of approximately 2 × 106 cells / ml were cultured with PEIpro TM The cell culture was transfected with the expression plasmids complexed with a transfection reagent (Polyplus) at a concentration of 0.5 mg / l. 72 hours after transfection, the cell pellets were collected by centrifugation and stored at -80°C for cell lysis and subsequent protein purification.
[0365] Purification and characterization of MYBPC3
[0366] Frozen cells were thawed and resuspended in 50 mM HEPES (pH 7.5), 300 mM NaCl, 5 mM MgCl2, 5% glycerol, 0.1% Tween 20. Immediately before use, protease inhibitors (10 tablets / 100 ml, completely EDTA-free (Roche)) and DNase I were added to the buffer. A Potter-Elvehjem homogenizer was used for cell lysis.
[0367] For purification, the clarified lysate was applied to IMC chromatography. His-tagged myBC3 was eluted with imidazole and dialyzed into the following elution buffer: 50 mM HEPES (pH 7.5), 150 mM NaCl, 6.5% sucrose. Monomeric MYBPC3 was obtained by a final polishing step of preparative size exclusion chromatography using a Superose 200increase column.
[0368] The purified MYBPC3 was characterized by SDS Page (a) and SEC-RALS HPLC (b) as a monomeric glycosylated protein with a purity of >85%. Figure 1 Shown in.
[0369] Example 2: Immunization and Antibody Screening by ELISA
[0370] Rabbit immunization (B cell antibody)
[0371] To generate antibodies against structural parts of MYBPC3, rabbits were immunized with recombinant purified immunogens (MYBPC3-Avi-His; see above). Blood samples (30 mL) were collected from immunized rabbits 42 days after immunization. The blood samples were purified and B cells were isolated by single cell sorting (FACS). The isolated cells were inoculated by using feeder cells. The reactivity of the test supernatant to native recombinant MYBPC3 was determined by ELISA and further analyzed by initial kinetic screening using surface plasmon resonance spectroscopy (SPR) (called Biacore) (next section).
[0372] ELISA screening was performed using supernatants from B cell cultures in either the 96 or 384 microtiter assay format, respectively (see Figure 2 ).
[0373] B cells producing positive MYBPC3-specific antibodies were subcloned into appropriate expression vectors (E. coli) and recombinantly expressed (heavy and light chains) in HEK293 cells. Supernatants of appropriate clones were removed for further studies.
[0374] The following clones were removed: 4H4, 4H7, 4H11, 5B8, 6C6, 6G5, 7B5, 7D5, 8H1, 11F2, 13F11, 14G6, 25G6, 25H1.
[0375] Mouse immunization (hybridoma)
[0376] To generate mouse antibodies against structural parts of myBP3, Balb / c- and NMRI- mouse strains were immunized with recombinant purified immunogen (MYBPC3-Avi-His; see above). After immunization, spleens of immunized animals were prepared and fused with myeloma cells (Ag8). The resulting hybridoma cells were cultured and analyzed by ELISA (see Figure 2 ) and the SPR-based kinetic screening described below to test the reactivity of the supernatant to rec MYBPC3. Single clones were generated using positive primary cultures. After cultivation, the supernatant was tested again for reactivity to MYBPC3. Positive clones were then cultured in large quantities (CELLine) and removed for further study.
[0377] Remove the following supernatants containing monoclonal antibodies: clones 4.1.1, 4.2.1, 4.6.6, and 4.7.10.
[0378] Example 3: Preliminary kinetic screening by SPR
[0379] Surface plasmon resonance (SPR) spectroscopy-assisted kinetic screening and detailed characterization using GE Healthcare Biacore TM 3000, T200 or 8K+ instruments.
[0380] Functionalization of the sensor-amine coupled capture system:
[0381] Rabbit or mouse antibody capture systems were immobilized on the CM5 sensor surface. Polyclonal goat anti-rabbit IgG Fc capture antibody GARbFcγ (code number 111-005-046; Jackson Immuno Research) or polyclonal rabbit anti-mouse IgG Fc capture antibody pAb was immobilized on the CM5 sensor surface using EDC / NHS chemistry at a density of 9000RU to 15000RU according to the manufacturer's instructions. <m-igg>Rb-IgG (GE Healthcare BR-1008-38) or polyclonal rabbit anti-mouse IgG Fc RAM Fcγ (code number 315-005-046, Jackson Immuno Research) was amine coupled.
[0382] Kinetic Characterization of Antibody Interactions:
[0383] All MYBPC3 interactions were analyzed at 37° C. The system buffer was HBS-ET (pH 7.4), 10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.05% (w / v) Tween 20. The system buffer was supplemented with 1 mg / mL CMD (carboxymethyl dextran, Cat. No. 86524) and used as the sample buffer for preparing the dilution series.
[0384] When using an 8K instrument, flow cell (Fc) 1 of channels 1 to 8 was used as a reference, and Fc2 of channels 1 to 8 was used for interaction measurements. When using a B3000 or T200 instrument, Fc1 was used as a reference, and Fc2, 3, and 4 were used for interaction measurements.
[0385] Anti-MYBPC3 antibody supernatants were diluted 1:3 to 1:5 (mouse) or 1:100 (rabbit) with sample buffer and injected for 2 minutes.
[0386] The antibody capture level (CL) was monitored in resonance units (RU). Next, 150 nM MYBPC3 (Roche in-house, 38.7 kDa) for kinetic screening was injected over the surface displayed anti-MYBPC3 antibodies at a rate of 30 μl / min or 60 μl / min.
[0387] The analyte association phase was monitored for 3 minutes and the dissociation phase was monitored for 5 minutes (kinetic screening).After each measurement cycle, the capture system was regenerated by subsequent injection of 10 mM glycine buffer (pH 2.0 and pH 2.25) at 20 μL / min for 60 seconds or according to the manufacturer's instructions.
[0388] Binding characteristics were analyzed by BIAcore TM Monitored by B3000 Control and Evaluation Software V4.1, T200 Control Software 2.0.1 and Evaluation Software 3.0, or 8K Control Software V3.0.11.15423, and via BIAcore TM Insight evaluation software V3.0.11.15423 was used for evaluation.
[0389] In addition, the kinetic data were interpreted by reporter point characterization and kinetic determination. Antibody / antigen binding stability was characterized using two reporter points, the signal recorded shortly before the end of analyte injection, the late analyte binding phase (BL), and the signal shortly before the end of the dissociation time, the late stability phase (SL).
[0390] The half-life of the antibody / antigen complex is calculated in minutes according to the following formula:
[0391] t / 2diss=ln(2) / (kd*60).
[0392] The molar ratio, i.e. the stoichiometric ratio of the combination, is calculated by the following formula:
[0393] MR=BL(antigen)*MW(antibody) / (MW(antigen)*CL(antibody)).
[0394] Figure 3 Shown is the kinetic curve of antibody binding to MYBPC3 at 37°C from mouse supernatant.
[0395] Example 4: Assay Development
[0396] Tested on ELISA-MTP platform
[0397] The assay is in the form of a sandwich ELISA, in which the biotinylated antibody is bound to a streptavidin-coated microtiter plate (MTP) and a digoxigenin (DIG)-labeled detection antibody. Both antibodies are specific for MYBPC3. Next, an anti-DIG antibody labeled with peroxidase is bound to DIG. Then, tetramethylbenzidine (TMB) is added and the reaction is stopped by adding sulfuric acid. Substrate turnover is photometrically detected at 450 nm using a photometric MTP reader, and the result at 540 nm is used as a reference.
[0398] To test for efficient antibody binding, the recombinantly expressed N-terminal MyBPC fragment (1-330) (immunogen as described above) was used as sample.
[0399] Table 1: Screening of mouse mAbs for optimal discrimination of 1 ng / ml MYBPC3 versus blank
[0400]
[0401] Conclusion: While mABs 4.1.1 and 4.7.10 did efficiently form a sandwich complex with MYBPC3, 4.6.6 was less suitable and was deselected for further development.
[0402] Next, the formation of orthogonal sandwich complexes containing mouse and rabbit antibodies was tested in an ELISA-MTP format.
[0403] Table 2: Testing of orthogonal complex formation between mouse and rabbit mAbs, screening for best discrimination of 2.7 pg / ml MYBPC3 versus blank.
[0404]
[0405]
[0406] Conclusion: Orthogonal sandwich complex formation is possible.
[0407] The final selection of the best sandwich antibody pairs was performed on the Elecsys platform.
[0408] Tested on Elecsys systems:
[0409] use An electrochemiluminescent immunoassay (ECLIA) for the specific measurement of MYBPC3 in particular human serum or plasma samples has been developed for the cobas analyzer e601. The Elecsys MYBPC3 immunoassay is an electrochemiluminescent immunoassay (ECLIA) that works by the sandwich principle. Two antibodies are included in the assay, one is a biotinylated monoclonal antibody candidate as a capture antibody and the other is a ruthenium-ylated monoclonal antibody candidate as a detection antibody, which form a sandwich immunoassay complex with MYBPC3 in the sample (here again the immunogen as described previously is used as the MYBPC3 sample). The complex is then bound to solid phase streptavidin-coated microparticles. These are magnetically captured on the electrode surface, resulting in chemiluminescent emission when a voltage is applied to the electrode, which is measured by a photomultiplier tube. The results are determined by an instrument-specific calibration curve, which is determined by a series of 5 calibrators with different concentrations of MYBPC3 over the entire measuring range. The samples are measured by pipetting volumes of 50ul sample, 60ul reagent 1 (R1), 60μl reagent 2 (R2) and 30μl magnetic beads. R1 contained the biotinylated mAb in phosphate reaction buffer, and reagent 2 (R2) contained the ruthenium-conjugated mAb in the same reaction buffer.
[0410] A high-sensitivity detection limit was set as the selection criterion for identifying the most suitable monoclonal antibody sandwich pairs.
[0411] Table 3: Assay in Elecsys format - screening of various mouse mAB:rabbit mAB and rabbit mAB:rabbit mAB combinations for best discrimination of 0.9 pg / ml MYBPC3 (3a) and 2.7 pg / ml MYBPC3 (3b) relative to blank.
[0412]
[0413]
[0414]
[0415] Conclusion: After testing various combinations, the top three pairs were 7B5 / 4.1.1, 13F11 / 4.1.1 (best performing at 0.9 and 2.7 pg / mL), and 7D4 / 4.1.1 (slightly less efficient).
[0416] Table 4: Head-to-head comparison of the top 3 mAb combinations within the high sensitivity detection range (0 to 2000 pg / ml MYBPC3)
[0417]
[0418] Conclusion: Choose 7B5 / 4.1.1.
[0419] Example 5: Detailed Characterization of SPR-Selected Antibody 7B5 / M-4.1.1
[0420] Unless otherwise stated, further detailed kinetic characterization using SPR was performed as described in Example 3 "Initial kinetic screening via SPR".
[0421] Purified antibodies were diluted to 1 nM to 5 nM and surface displayed via the capture system.A concentration series of MYBPC3 between 0.4 nM and 90 nM with a dilution factor of 3 was analyzed instead of a single concentration.
[0422] The analyte binding phase was monitored for 3 minutes, and the dissociation phase was monitored for 10 minutes, or 30 minutes for a concentration of 30 nM measured in duplicate.
[0423] For the evaluation, the kinetic rate constants and the dissociation equilibrium constant K were determined according to BIAcore SW using a Langmuir 1:1 fitting model. D Secondly, a Langmuir 1:1 fit was applied to Scrubber-SW V2.0c.
[0424] Kinetic characterization
[0425] Binding profiles for detailed characterization of mAbs 7B5 and M-4.1.1 showed rapid MYBPC3 complex formation, approaching antibody saturation at 30 nM MYBPC3. A 30 min dissociation phase showed sufficiently high complex stability for both antibodies. The interaction obeys Langmuir's law, see Figure 4 .
[0426] The results of the kinetic constants obtained are summarized in Table 5. Both antibodies bound MYBPC3 with high affinity in the picomolar range.
[0427] Table 5: Kinetic constants and affinities of clones 7B5 and M-4.1.1
[0428]
[0429] Sandwich complex formation via SPR
[0430] Sandwich complex formation of antibodies M-4.1.1 and 7B5 in GE Healthcare BIAcore TM The test was performed at 25°C on a B3000 instrument.
[0431] Biotinylated antibody M-4.1.1-Bi was used as primary antibody and 7B5 was used as secondary antibody, which were injected into the pre-complexed antibody-antigen complex M-4.1.1 / MYBPC3.
[0432] The CAP sensor surface was used according to the manufacturer's instructions. To achieve reversible capture, the CAP reagent was injected at a flow rate of 2 μL / min for 5 minutes. Next, 20 nM M-4.1.1-Bi was injected at a flow rate of 10 μL / min onto Fc2 for 3 minutes. Fc1 was used as a reference and saturated with 50 nM amino-PEO-biotin (Sigma Aldrich); 150 nM MYBPC3 or buffer as a negative control was injected at a flow rate of 30 μL / min for 3 minutes; finally, the secondary antibody 200 nM 7B5 or buffer as a control was injected for 3 minutes and then dissociated for 1 minute. After each cycle, the system was regenerated according to the manufacturer's instructions.
[0433] Using BIAcore TM The software in the B3000 Control and Evaluation Software V4.1 monitors and evaluates immune complex stability. Sandwich complex formation experiments were interpreted by visual inspection. Epitope accessibility was quantified as a molar ratio by forming the ratio between the resonance units of the secondary antibody binding response signal and the capture level of the primary antibody.
[0434] The antibody pair M-4.1.1 and 7B5 form a sandwich complex with MYBPC3. The two antibodies recognize different epitopes of their target MYBPC3. The sensor image using the antibody M-4.1.1 presented on the sensor surface and 7B5 used as a secondary antibody to form a sandwich complex is shown in Figure 2. Figure 5 shown.
[0435] Figure 5 The top sensorgram shows MYBPC3 binding to surface presented M-4.1.1 followed by injection of secondary antibody 7B5 to form a sandwich complex. The middle sensorgram shows MYBPC3 injection followed by injection of buffer as a negative control in place of the secondary antibody. The bottom 2 sensorgrams show negative controls where buffer was injected in place of MYBPC3 and the secondary antibody, and where buffer was injected in place of MYBPC3 and the secondary antibody 7B5, respectively. Example 6: Epitope Characterization
[0436] Peptide Mapping for Linear Peptides
[0437] Epitope mapping of antibody clones was performed by an immobilized peptide library (length: 15 amino acids) corresponding to the canonical sequence (1-392) of human MYBPC3. Cysteine residues were replaced by serine. Peptides were synthesized on modified cellulose discs using an automated synthesizer (Intavis MultiPep RS) and dissolved after synthesis. Solutions of individual peptides were then spotted onto coated microscope slides. The synthesis was performed stepwise on amino-modified cellulose discs in 384-well synthesis plates using 9-fluorenylmethoxycarbonyl (Fmoc) chemistry. In each coupling cycle, the corresponding amino acids were activated with a solution of DIC / HOBt in DMF. Between coupling steps, unreacted amino groups were capped with a mixture of acetic anhydride, diisopropylethylamine and 1-hydroxybenzotriazole. After the synthesis was completed, the cellulose discs were transferred to a 96-well plate and treated with a mixture of trifluoroacetic acid (TFA), dichloromethane, triisopropylsilane (TIS) and water for side chain deprotection. After removal of the lysis solution, the cellulose-bound peptides were dissolved with a mixture of TFA, TFMSA, TIS and water, precipitated with diisopropyl ether and resuspended in DMSO. These peptide solutions were then spotted onto Intavis CelluSpots using the Intavis slide spotting robot. TM On a glass slide.
[0438] For epitope analysis, the prepared slides were washed with ethanol, then with Tris buffered saline (TBS; 50mMTris, 137mM NaCl, 2.7mM KCl, pH 8), and then blocked for 1 hour at 37°C with 5mL 10x Western Blocking Reagent (Roche Applied Science), TBS containing 2.5g sucrose, 0.1% Tween 20 for a blocking step. After washing (TBS + 0.1% Tween 20), the slides were incubated with antibody clone solution (1μg / mL) in TBS + 0.1% Tween 20 for 1 hour at 37°C. After washing, the slides were incubated with anti-mouse or anti-rabbit secondary HRP antibodies (1:20000 in TBS-T) for detection, and then incubated with DAB substrate. Positive SPOTs were assigned to the corresponding peptide sequences.
[0439] Table 6
[0440]
[0441]
[0442] *Commercially available antibodies against MYBPC3: G7, G1, E7, and F1 are available from Santa Cruz, AF7439 is available from R&D Systems
[0443] Conclusion: The epitopes of the selected clones 7B5 and M-4.1.1 do not overlap with the epitopes disclosed by King's College in WO2015110114 and WO215110115, nor do they overlap with the epitopes of the commercially available clones M-G1 and M-F1. The epitopes of the selected clones 7B5 and M-4.1.1 may not be linear.
[0444] HD-X: Hydrogen / Deuterium Exchange Mass Spectrometry
[0445] Antigen: MYBPC3
[0446] Antibody 1: 7B5
[0447] Antibody 2: M.4.1.1
[0448] experiment
[0449] Hydrogen / deuterium exchange mass spectrometry
[0450] The MYBPC3 antigen was labeled with deuterium by incubation in buffered deuterated water (D2O) for different times under the following conditions:
[0451] a) In the absence of antibody (protein state 1)
[0452] b) In the presence of antibody 7B5 (protein state 2)
[0453] c) In the presence of antibody M.4.1.1 (protein state 3).
[0454] After different labeling times, the exchange reaction was quenched by adding quenching buffer.
[0455] Subsequently, all samples were protease digested with Nepenthes protease-2, and the resulting peptides were separated by reversed-phase UPLC and identified by MS / MS detection using a Thermo Orbitrap Fusion Lumos mass spectrometer.
[0456] For data evaluation to identify peptides with different deuteration levels in the MYBPC3 antigen in protein states 1, 2 and 3, respectively, the software tools PeaksStudio commercially available from Bioinformatics Solutions Inc. (BSI) and HDExaminer commercially available from Sierra Analytics were used.
[0457] The experimental details are as follows:
[0458] A) Tools, reagents and solutions:
[0459] antigen:
[0460] MYBPC3, c = 0.5 mg / ml, in 50 mM HEPES, 150 mM NaCl, 6.5% sucrose (pH 7.5)
[0461] Antibody 1:
[0462] 7B5, c = 2.1 mg / ml, in 50 mM KPP, 150 mM KCl (pH 7.5)
[0463] Antibody 2:
[0464] M.4.1.1, c = 28.4 mg / ml in 50 mM KPP, 150 mM KCl (pH 7.5)
[0465] H2O Buffer:
[0466] 50 mM potassium phosphate buffer, 150 mM KCl, pH 7.5, in H2O
[0467] D2O Buffer:
[0468] 50 mM potassium phosphate buffer, 150 mM KCl, pH 7.5 in D2O.
[0469] Quenching Buffer:
[0470] 4M urea, 0.17M KH2PO4, 0.3M TCEP, pH 2.8
[0471] Pipetting and labeling robots:
[0472] Leap Technologies, PAL HTC Autosampler
[0473] Protein state 1 (antigen only):
[0474] 72.38 μl of antigen were diluted with 44.62 μl of H2O buffer and provided in the 0°C tempered sample holder of the robot.
[0475] Protein state 2 (antigen plus 7B5):
[0476] 72.38 μl of antigen was added to 37.44 μl of 7B5 and diluted in 7.18 μl of H2O buffer, also provided in a 0°C tempered sample holder.
[0477] Protein state 3 (antigen plus M.4.1.1):
[0478] 72.38 μl of antigen were added to 7.02 μl of M.4.1.1 and diluted in 37.6 μl of H2O buffer, also provided in a 0°C tempered sample holder.
[0479] Marking time:
[0480] 0min
[0481] 15s
[0482] 1min, 10min, 60min, 300min
[0483] B) Deuterium labeling of unbound (protein state 1) and bound (protein states 2 and 3) MYBPC3
[0484] B1) Peptide identification and 0 min labeling time followed by quenching (no deuteration control):
[0485] The robot dilutes 5.2 μl of protein state 1 into 46.8 μl of H2O buffer at 20° C. in the sample holder. 39 μl of this is pipetted and mixed into 39 μl of quenching buffer in a 0° C. tempered sample holder. After a 20 s quenching time, 50 μl of this sample is injected into the measurement system.
[0486] B2) Different labeling times (15 s, 1 min, 10 min, 60 min and 300 min) and subsequent quenching:
[0487] The robot dilutes 5.2 μl of protein state 1 into 46.8 μl of D2O buffer in a sample holder at 20° C. After the corresponding labeling time, 39 μl of this is pipetted and mixed into 39 μl of quenching buffer in a 0° C. tempered sample holder. After a 20 s quenching time, 50 μl of this sample is injected into the measurement system.
[0488] The same procedure was performed for protein states 2 and 3.
[0489] All labeling samples (0 min, 15 s, 1 min, 10 min, 60 min and 300 min labeling) were performed in triplicate.
[0490] C) Analysis of deuterium-labeled samples:
[0491] The samples from B) were loaded onto a cooled (0°C) Waters NanoAcquity UPLC system (WatersCorp., Milford, MA). Online Nepenthes protease-2 digestion (Affipro, #AP-PC-004) was performed at 20°C. The obtained peptides were captured and desalted for 3 min at 0°C (0.23% formic acid in water, 200 μl / min, Waters VanGuard C18, 1.7 μm, 2.1x5 mm). Subsequently, all samples were subjected to reverse phase separation (Waters BEH C18, 1.7 μm, 1x100 mm) using a gradient of 0.23% formic acid in acetonitrile (pH 2.5) increasing from 8% to 35% in 7 min at a flow rate of 40 μl / min.
[0492] Mass spectrometry was performed on a Thermo Orbitrap Fusion Lumos mass spectrometer using positive ion electrospray.
[0493] For peptide identification using the 0 min labeling time sample (B1), the first replicate was measured using high energy collision dissociation (HCD), the second replicate was measured using electron transfer dissociation, and the third replicate was measured using electron transfer / high energy collision dissociation (EThcD); all in data dependent acquisition (DDA) mode. For all labeling measurements, full scan mode was sufficient.
[0494] D) Data evaluation:
[0495] Peptide identification was performed using Peaks Studio (Bioinformatics Solutions Inc. (BSI)) according to the supplier's instructions. Deuterium incorporation in peptides obtained from different labeling times was determined using HDExaminer (Sierra Analytics) according to the supplier's instructions and compared to a non-deuterated control (0 min labeling time).
[0496] Summary of results:
[0497] Table 7
[0498]
[0499] Table 8
[0500]
[0501] Conclusion: The selected antibodies 7B5 and M-4.1.1 indeed recognize the non-linear conformational epitope presented by the natively folded MYBPC3 protein.
[0502] Example 7: Elecsys assay
[0503] Biomarker Measurement (Exemplary Methods for Detecting MYBPC3)
[0504] The commercial MYBPC3 from Roche Diagnostics (Mannheim, Germany) was used. The reagents measure serum and plasma concentrations of the biomarker MYBPC3. A prototype from Roche Diagnostics (Mannheim, Germany) was used. Reagents to measure the biomarker MYBPC3.
[0505] Use biotinylated rabbit MAB <mybpc3>rK / M-7B5-F(ab')2-Bi and ruthenium MAB <mybpc3>MYBPC3 assay was performed using rH-4.1.1-IgG-P8-sulfoRu. An electrochemiluminescent immunoassay (ECLIA) for the specific measurement of MYBPC3, in particular in human serum or plasma samples, has been developed for the cobas analyzer e601. The Elecsys MYBPC3 immunoassay is an electrochemiluminescent immunoassay (ECLIA) that works on the sandwich principle. The assay contains two antibodies, namely a biotinylated monoclonal antibody F(ab')2-fragment MAB <mybpc3>(MAB<MYBPC3_1-330> Bi; capture antibody, such as 7B5) and ruthenium-containing monoclonal anti-MYBPC3 antibody MAB <mybpc3>(MAB<MYBPC3_1-330> -Ru; detection antibody, such as 4.1.1), forms a sandwich immunoassay complex with MYBPC3 in the sample. The complex is then bound to solid phase streptavidin-coated microparticles. These are magnetically captured to the electrode surface, resulting in chemiluminescent emission when a voltage is applied to the electrode, which is measured by a photomultiplier tube. The results are determined by an instrument-specific calibration curve, which is determined by a series of 5 calibrators with different concentrations of MYBPC3 over the entire measuring range. Samples were measured using assay protocol 2 with a pipetting volume of 50ul sample, 60ul reagent 1 (R1), 60μl reagent 2 (R2) and 30μl magnetic beads. R1 contains MAB in phosphate reaction buffer <mybpc3>F(ab`)2-Bi, reagent 2 (R2) in the same reaction buffer containing MAB <mybpc3>-Ru.
[0506] Example 8: Assay performance: Roche-Erenna head-to-head comparison
[0507] To evaluate the clinical utility of our in-house developed MYBPC3 assay, the performance of our assay was compared with that of an established high-sensitivity MYBPC3 (alias MYBPC3) assay on the Erenna platform available from Millipore Sigma. The performance of the assay was published in the clinical studies BASEL V (Kozhuharov et al. (2021)) and APACE (Kaier et al. (2022)). The BASEL V study was designed to enable rapid triage of patients suspected of having acute heart failure (AHF), while the APACE study focused on providing accelerated rule-out and rule-in decisions in cases of myocardial infarction (MI).
[0508] Comparison of Erenna–Roche on BASEL V dataset:
[0509] Data: Head-to-head comparison between the MYBPC3 Roche assay and the MYBPC3 Erenna assay based on the BASEL V dataset. Published Basel V study analyzed using the Erenna assay: Kozhuharov et al. Eur J Heart Fail. 2021 May;23(5):716-725. doi:10.1002 / ejhf.2094. Epub 2021 Feb 5 PMID:33421273.
[0510] Results relevance:
[0511] Matched Roche and Erenna MYBPC3 measurements were obtained for a total of 837 patients. The correlation between the two assays was high (Pearson correlation = 0.894 after log transformation). Figure 6 Shown in.
[0512] Results Clinical manifestations:
[0513] Diagnosis of Heart Failure: In this analysis, there were 837 unique patients, of which 444 had heart failure. The Roche MYBPC3 assay had a higher AUC compared to the Erenna assay (see graph). A one-sided DeLong test was used to compare the AUCs, and the results showed high significance (p value = 7.878e-09). Figure 7 Shown in.
[0514] Comparison of Erenna–Roche on APACE dataset:
[0515] Data: Head-to-head comparison between the MYBPC3 Roche assay and the MYBPC3 Erenna assay is based on the APACE dataset. Public APACE studies analyzed using the Erenna assay: Kaier et al., A 0 / 1h-algorithm using cardiac myosin-binding protein C for early diagnosis of myocardial infarction, European Heart Journal. Acute Cardiovascular Care, Volume 11, Issue 4, April 2022, Pages 325-335.
[0516] Correlation of results: For a total of 1056 patients, matched Roche and Erenna MYBPC3 measurements were obtained. The correlation between the two assays was high (Pearson correlation = 0.9726981). Figure 8 shown.
[0517] Results Clinical manifestations:
[0518] 1) Diagnosis of MI: In this analysis, there were 992 unique patients, of which 205 patients had MI (NSTEMI and STEMI). The Roche MYBPC3 assay had a higher AUC compared to the Erenna assay. A one-sided DeLong test was used to compare the AUCs, and the results showed significance (p value = 0.02269). Similar performance was observed in the inclusion zone (lower left), and slightly better performance was observed in the exclusion zone (upper right). The results are shown in Fig. 9 shown.
[0519] 2) Differentiation of type 1 from type 2 MI: There were a total of 52 type 2 and 153 type 1 cases. The AUC of the Roche assay was higher. The DeLong test did not show significance (p value = 0.1387). Fig.10 Shown in.
[0520] 3) Risk prediction of major adverse cardiovascular events (MACE) within 30 days: This analysis was based on follow-up data of 986 patients within 30 days after visiting the emergency room. 204 patients had MI as the index event (NSTEMI and STEMI), 3 patients developed MI during the follow-up period, and 2 patients died (cardiac and non-cardiac deaths were taken into account). The Roche MYBPC3 assay had a higher AUC compared to the Erenna assay. The AUC was compared using a one-sided DeLong test, and the results showed significance (p-value = 0.0232). Similar performance was observed in the inclusion area (lower left), and slightly better performance was observed in the exclusion area (upper right). The results are as shown in Fig.12 shown.
Claims
1. A kit comprising i) a first monoclonal antibody or an antigen-binding fragment thereof, which binds to MYBPC3 (myosin binding protein C, cardiac type), wherein the first monoclonal antibody or the antigen-binding fragment thereof comprises a first light chain variable domain and a first heavy chain variable domain, wherein a) the first light chain variable domain comprises the sequence shown in SEQ ID NO:7 (DIVMTQTPASVEAAVGGTVTIKCQASQSIGNALAWYQQKPGQPPKLLIYSTSYLPSGVPSRFKGGGSGAEYTLTISDLECADAATYYCQSYYVSTSSSDRSSFGGGTEVVVK), and b) the first heavy chain variable domain comprises the sequence shown in SEQ ID NO: 8 (QEQLEESGGGLVKPGGTLTLTCKVSGFDFSSGYDMCWVRQAPGKGLESIACIGSSSASTWYANWVNGRFTVSRSTSLNTVDLKMTSLTVADTATYFCARESSTEYYYNLWGPGTLVTVSS), as well as ii) a second monoclonal antibody or an antigen-binding fragment thereof, which binds to MYBPC3 (Myosin Binding Protein C, Cardiac Type), wherein the second monoclonal antibody or the antigen-binding fragment thereof comprises a second light chain variable domain and a second heavy chain variable domain, wherein a) the second light chain variable domain comprises the sequence shown in SEQ ID NO: 15 (DILMTQSPAILSVSPGERVSFSCRASQNIGTNMHWYQQRTNGSPRLLIRFASESFSGIPSRFSGTGSGTDFTLRINSVESEDIADYYCQQSYNWPFTFGAGTKLELK), and b) the second heavy chain variable domain comprises the sequence shown in SEQ ID NO: 16 (QVQLKESGPGLVAPSQSLSITCTVSGFSLTGYGVNWVRQPPGKGLEWLGMIWGDGSTDYNSVYKSRLSISKDNSKSQVFLKMNSLQTDDTARYYCARRDTGGASMDYWGQGTSVTVSS). 2 . The kit according to claim 1 , wherein the kit comprises i) a biotinylated F(ab′) 2 fragment of the first monoclonal antibody and ii) a ruthenium-ylated second monoclonal antibody.
3. A monoclonal antibody or a fragment thereof, which binds to MYBPC3 (myosin binding protein C, cardiac type), wherein the monoclonal antibody or the fragment thereof is selected from i) a first monoclonal antibody or a fragment thereof comprising a first light chain variable domain and a first heavy chain variable domain, (a) the first light chain variable domain comprises (a1) a first light chain CDR1 having the sequence shown in SEQ ID NO: 1 (QASQSIGNALA), (a2) a first light chain CDR2 having the sequence shown in SEQ ID NO: 2 (STSYLPS), and (a3) a first light chain CDR3 having the sequence shown in SEQ ID NO: 3 (QSYYVSTSSSDRSS), (b) the first heavy chain variable domain, which comprises (b1) a first heavy chain CDR1 having the sequence shown in SEQ ID NO:4 (SGYDMC), (b2) a first heavy chain CDR2 having the sequence shown in SEQ ID NO:5 (CIGSSSASTWYANWVNG), and (b3) a first heavy chain CDR3 having the sequence shown in SEQ ID NO:6 (ESSTEYYYNL), or ii) a second monoclonal antibody or a fragment thereof, comprising a second light chain variable domain and a second heavy chain variable domain, wherein (a) the second light chain variable domain comprises (a1) a second light chain CDR1 having the sequence shown in SEQ ID NO:9 (RASQNIGTNMH), (a2) a second light chain CDR2 having the sequence shown in SEQ ID NO: 10 (FASESFS), and (a3) a second light chain CDR3 having the sequence shown in SEQ ID NO: 11 (QQSYNWPFT), (b) the second heavy chain variable domain, which comprises (b1) a second heavy chain CDR1 having the sequence shown in SEQ ID NO: 12 (GYGVN), (b2) a second heavy chain CDR2 having the sequence shown in SEQ ID NO: 13 (MIWGDGSTDYNSVYKS), and (b3) The second heavy chain CDR3 has the sequence shown in SEQ ID NO: 14 (RDTGGASMDY).
4. The monoclonal antibody or fragment thereof according to claim 3, wherein i) the first light chain variable domain comprises the sequence shown in SEQ ID NO:7, and the first heavy chain variable domain comprises the sequence shown in SEQ ID NO:8, ii) the second light chain variable domain comprises the sequence shown in SEQ ID NO:15 and the second heavy chain variable domain comprises the sequence shown in SEQ ID NO:
16.
5. The monoclonal antibody or fragment thereof according to claim 3 or 4, wherein the fragment is a Fab fragment, a Fab' fragment, a Facb fragment, a F(ab')2 fragment, a scFv fragment or a Fv fragment, in particular, wherein the fragment is a F(ab')2 fragment.
